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AGE-RELATED HOST FACTORS REGULATE 
LUNG CANCER PROGRESSION 
 
John Caleb Greenwell 
November 14th, 2017 
 
Cancer is largely a disease of the elderly. In the United States alone, 87% of all 
cancers in 2017 will be diagnosed in individuals aged 50 years or older. Among 
them, lung cancer is the deadliest, accounting for 1 in 4 cancer deaths. The 5-year 
survival rate is below 20%, a number which has not changed substantially over the 
past several decades. This underscores a desperate need for new strategies in 
prevention, early detection and treatment of this deadly disease. While tobacco 
use is unquestionably the number one risk factor for the development of lung 
cancer, the majority of diagnoses occur in individuals with preexisting lung 
conditions such as chronic obstructive pulmonary disease and idiopathic 
pulmonary fibrosis, characterized by inflammation and remodeling of the 
extracellular matrix. Fibronectin is one matrix protein upregulated in these settings. 
Fibronectin EDA is a splice variant of fibronectin that is increased with aging and 
has been shown to be a vascular marker for solid tumors and metastases. 
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Moreover, immunization against fibronectin EDA decreases tumor burden and 
lung metastases in the MMTV-PyMT transgenic model of metastatic mammary 
carcinoma.  
In this dissertation, I explore how age-related host factors regulate lung 
progression. More specifically, I examine how tissue remodeling and aging act in 
concert, through increased levels of fibronectin EDA, to render the host susceptible 
to lung cancer progression. This and other work is described in 5 chapters: 1) 
background and introduction; 2) the role of aging and tissue remodeling in lung 
cancer; 3) the role of fibroblasts in lung cancer; 4) the role of sex and redox in lung 
cancer; and 5) summary and discussion. The work described here suggests that 
age-dependent host factors influence lung cancer progression. Importantly, lung 
inflammation/tissue remodeling augments pulmonary metastasis in the aging lung, 
but not in young lungs, through mechanisms involving fibronectin EDA, which 
perhaps provides a scaffold for tumor cell migration/organization and proliferation. 
This points to an interplay between lung aging and inflammation/remodeling in lung 
tumor progression and describes a previously unknown role of fibronectin EDA in 
lung cancer in the setting of lung injury and aging.  Sex also appears to be 
important, while oxidative stress may play a minor role.  Finally, we show that 
fibroblasts produce factors capable of influencing cancer progression.   
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BACKGROUND AND INTRODUCTION 
 
1.1 Epidemiology of Lung Cancer 
Lung cancer is the leading cause of cancer death in men and women in the 
Unites States (US). It is largely preventable, as most cases are due to tobacco 
use. In 2017, there will be over an estimated 220,000 new cases of lung cancer, 
which accounts for 14% of all cancer diagnoses [1]. Of those diagnosed, there will 
be over an estimated 155,000 deaths, which is more than the next 3 major types 
of cancer (colon, prostate, and breast) combined. Lung cancer is thus responsible 
for more than one-quarter (27%) of all cancer deaths [2]. Due to the large number 
of individuals affected by lung cancer, the national cost of lung cancer care in the 
US in 2010 was estimated to be $12.12 billion, a significant burden on the 
economy. Lung cancer was also found to be the condition with the highest cost in 
the last year of life phase of care [3]. These data justify further research and efforts 
in this area. 
 Lung cancer is diagnosed primarily in the elderly population. Cancer in 
general is well known to be a disease of the aged. In the US alone, 87% of all 
cancers in 2017 will be diagnosed in individuals 50 years or older. For lung cancer, 
two-thirds of all new cases will be diagnosed in those older than 65 years, while 
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the number of deaths from lung cancer in those under 20 years of age is expected 
to be 0% [1].  
The number one risk factor for the development of lung cancer is 
unquestionably tobacco exposure. This was first reported in 1964, when Luther 
Terry, the ninth Surgeon General of the United States, released his now famous 
report titled, “Smoking and Health: Report of the Advisory Committee to the 
Surgeon General of the United States,” which concluded that bronchitis and lung 
cancer were causally related to cigarette smoking. Of all lung cancer deaths, 80% 
are caused by smoking. This fact is strengthened by the striking geographic 
variation in lung cancer deaths by state, where patterns of mortality cluster in areas 
with the highest prevalence of smoking. Kentucky leads the nation in individuals 
who smoke, while Utah contains the fewest smokers. Not surprisingly, the number 
of lung cancer deaths in those states in 2017 is estimated to be 3560 compared to 
460, respectively [1].  While the carcinogenic mechanisms of tobacco use are not 
completely understood, research over the past 5 decades has revealed that we do 
indeed know a great deal about how tobacco use causes lung cancer and that 
there is certainly not a single mechanism, but several, responsible for tobacco 
carcinogenesis. There have been over 8000 compounds identified in tobacco and 
tobacco smoke [4]. Among them, the International Agency for Research on Cancer 
has classified over 70 carcinogens capable of causing cancer in laboratory animals 
and humans [5]. These carcinogens include the polycyclic aromatic hydrocarbons 
(PAHs) and the tobacco specific nitrosamines (TSNAs). Many require metabolic 
activation that then leads to the formation of DNA adducts by covalent binding. For 
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example, benzo[a]pyrene diol epoxide has been shown to bind to select regions of 
the p53 gene [6]. Overtime, DNA repair mechanisms fail, or are evaded, and due 
to the cumulative nature of these adducts, permanent mutations are formed. If 
these mutations occur in vital genes, oncogenes (e.g. KRAS) could be activated 
and tumor suppressor genes (e.g. p53 and Rb) could be deactivated leading to the 
development of cancer. While the contribution of such mutations in the 
development of cancer cannot be overstated, mutations alone are not sufficient to 
cause tumor growth. It has been shown that simultaneous expression of oncogenic 
KRAS and knockdown of p53 was insufficient to confer a complete malignant 
phenotype in human bronchial epithelial cells [7].  
While lung cancer is often viewed solely as a smoker’s disease, not all lung 
cancers occur in individuals who smoke [8]. This is an important fact to take note 
of because lung cancers that develop in those who have never smoked differ 
considerably from lung cancers in smokers. Significant differences in histologic 
subtypes have been identified, with adenocarcinoma prevailing in never smokers 
[9]. Exposure to radon gas, which can be trapped in residential homes, has been 
proposed as the second leading cause of lung cancer after cigarette smoking 
[10,11]. However, others have argued that studies showing an association 
between radon exposure and lung cancer relied on a linear-no-threshold 
hypothesis-based, risk assessment paradigm that has recently been invalidated. 
Instead, using a hormetic relative risk model, radon exposure was shown to 
actually protect against lung cancer [12]. Regardless, these studies establish the 
point that a large number of individuals who develop lung cancer are never-
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smokers, and the proportion of individuals who develop lung cancer that have 
never smoked is going to continually increase as smoking cessation efforts 
continue, and thus research in this area must continue [13]. 
The overall incidence of lung cancer has been declining, but this is due 
largely to smoking cessation efforts. For men, the incidence rate has been 
declining since the mid 1980s, while for women, the rate did not start declining until 
the early 2000s [2]. From 1990 to 2011, lung cancer death rates dropped by 36% 
for men and 11% for women from 2002 to 2011 [14]. This decrease in death rates 
matched a drop in the number of individuals smoking that began decades earlier. 
In fact, it has been estimated that the Surgeon General’s report in 1964 resulted in 
8 million fewer smoking-related deaths, with one-third of those being due to cancer. 
This was associated with a decline in adult smoking rates from 43% (1965) to 18% 
today [15]. Although this decline in smoking rates is to be celebrated, tobacco use 
remains a major problem in the US and worldwide. Every day, it is estimated that 
3200 youth smoke a cigarette for the first time, and 2100 youth and occasional 
smokers progress to become daily smokers [15]. There also appears to be a high 
-risk population of women born after 1950 in several Southern and Midwestern 
states [16]. Thus, continued efforts in raising awareness of the health hazards of 
tobacco use and additional interventions must be pursued in all areas of influence.  
 Unfortunately, the decline in the number of cigarette smokers in the US has 
been met by an increase in the number of electronic cigarette (e-cig) users. E-cigs 
are battery-powered devices that use heat to convert liquid nicotine and various 
flavorings into an inhalable vapor. E-cigs were invented in 2003 and introduced 
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into the market the following year as a “safe alternative” to cigarette smoking. Since 
then, the number of e-cig users has grown at an alarming pace, especially among 
the nation’s youth. Roughly 16% of current cigarette smokers and 22% of recent 
former smokers currently use e-cigs on a regular basis [17]. E-cig sales in the US 
are estimated to reach $10 billion in 2017, and are expected to surpass the sale of 
standard cigarettes by 2023 [18]. While e-cigs are marketed as safer alternatives 
to conventional cigarettes, numerous studies have shown that e-cigs contain 
carcinogens found in cigarettes, as well as several metals and silicate particles 
[19,20]. Long-term term studies evaluating the harmful effects of e-cigs and the 
ability of e-cig use to cause or promote lung cancer have not been investigated. 
However, due to their similar composition to conventional cigarettes (nicotine and 
carcinogens), the drastic increase of e-cig use is a matter of great concern, and 
additional studies are warranted in this area.  
 
1.2 Diagnosis, Management, and Treatment of Lung Cancer 
 There are currently 2 major recognized types of lung cancer: small-cell lung 
cancer (SCLC) and non-small-cell lung cancer (NSCLC), which is further divided 
into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [21]. 
SCLC is highly aggressive, exhibits neuroendocrine characteristics, and accounts 
for 15% of lung cancers. Of the remaining 85% of lung cancers, the vast majority 
are NSCLC, with adenocarcinoma being the most common, followed by squamous 
cell carcinoma, and lastly large cell carcinoma [14]. While smoking is associated 
with every type of lung cancer, the association is strongest for SCLC and 
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squamous cell carcinoma. In never smokers, adenocarcinoma is the most the 
common type identified [9,22].  
 Symptoms of lung cancer include persistent cough, coughing up blood, 
shortness of breath, wheezing, hoarseness, weight loss, chest pain, lethargy, and 
others.  A diagnosis is made using one or several of the following methods: 
physical exam, chest x-ray, CT scan, PET scan, MRI, bone scan, sputum cytology, 
bronchoscopy, or fine-needle aspiration biopsy of the lung. Once a diagnosis has 
been made, oncologists use the principles set forth by the American Joint 
Committee on Cancer for lung cancer staging. There are currently 4 recognized 
stages of lung cancer, staged 1 - 4, with stages 1, 2 and 3 being further divided 
into A and B subtypes [23]. Proper staging is of the utmost importance for the 
determination of the appropriate treatment regimen. For example, surgical 
resection is beneficial for patients with stages 1-2, while those with stages 3-4 
rarely benefit from surgery [24]. Other treatment options include chemotherapy 
alone or in combination with radiation.  
Despite the steady increase in survival rates for most cancers, the current 
relative 5-year survival rate for lung cancer is 18% and that number has only 
increased slowly over the past several decades [2]. The survival rate decreases to 
4% if distant metastases are present, which is a devastating reality because over 
50% of all diagnoses are in this category [14]. This is one of the main reasons for 
the low survival rate, largely due to the lack of symptoms until that time. This 
underscores the need for early detection in lung cancer. It has been argued that 
progress is being made in this area through recent developments in screening with 
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spiral computed topography, which has been shown to decrease lung cancer 
deaths in those who have a history of heavy smoking [25,26]. These reports, 
however, as some have warned, must be taken with caution, as they introduce 
lead time bias in survival rates [27]. Thus, age-adjusted mortality rates and not 
survival rates might be a better measure of lung cancer incidence.  
  
1.3 Aging 
 Aging is natural process of life that is unavoidable. It is largely due to the 
progressive accumulation of damage in macromolecules that is marked by a 
decline in the function of cells, tissues and ultimately organs. This decline in 
physiological integrity renders organisms vulnerable to cancer, cardiovascular 
disease, diabetes, and neurodegenerative diseases, among others.  
 Population aging, a process defined as an increase in the proportion of older 
people and a decrease in the number of younger people, is becoming a major 
problem in the US and worldwide. For example, in 1950 only 8% of the world’s 
population was over the age of 60. That number grew to 11.2% by 2011, and is 
projected to reach 22% by 2050. In contrast, the number of individuals under the 
age of 15 is projected to decrease from 26.6% to 20% in 2050 [28]. The cause of 
population aging is two-fold: one is a decrease in fertility rates, and two, increased 
life expectancies. In the US, the fertility rate, defined as births per 1000 women, is 
now the lowest it has ever been since such records started being kept more than 
a century ago [29]. Increases in life expectancy in the past have mainly been due 
to decreases in child mortality rates. Presently, however, increased life expectancy 
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is due to decreases in mortality in the elderly.  As the population continues to age, 
the prevalence of chronic diseases, known as noncommunicable diseases (NCDs) 
will continue to increase. In the US, 65% of health care costs are due to individuals 
with at least one NCD [30]. This will become a major threat to our economy, as the 
high health costs associated with NCDs will need to be sustained by a shrinking 
working-age population. 
While worldwide deaths from most NCDs (cancer and cardiovascular 
diseases) are continuing to decline, those from chronic obstructive pulmonary 
disease (COPD) are not and some estimate that they are growing. In fact, diseases 
of the respiratory system are among the major contributors of the worldwide 
burden of disease. For example, there are over 1 billion people globally who suffer 
from chronic respiratory diseases such as asthma (300 million) and COPD (210 
million) [31], with COPD expected to become the third leading cause of death by 
2030 [32]. These respiratory diseases are disproportionately observed in the 
elderly population [33,34], and may actually be underrepresented [35]. 
 The association between aging and an increased susceptibility to 
respiratory diseases has also been noted in several rodent models. For example, 
old animals were shown to be more susceptible to bleomycin-induced pulmonary 
fibrosis, and morphologic and functional changes due to chronic cigarette smoke 
inhalation [36,37]. Old animals were also more susceptible to lung injury in the 




1.4 Lung Tissue Remodeling 
As previously mentioned, historically, lung cancer was thought to be caused 
directly by mutations in the genome initiated by tobacco carcinogens. However, 
numerous studies have shown that COPD and fibrotic diseases such as asbestosis 
and idiopathic pulmonary fibrosis (IPF), characterized by inflammation and lung 
tissue remodeling, are also risk factors for the development of cancer. For 
example, as early as 1935, through autopsy studies, Gloyne identified cases of 
squamous cell carcinoma in individuals with asbestosis [39]. Several decades 
later, Haddad & Massaro, again through autopsy studies, found lung cancer 
lesions in individuals with IPF [40].  More recently, Hubbard and colleagues found 
a seven-fold increase in the incidence of lung cancer in those with IPF (termed 
cryptogenic fibrosing alveolitis in their study) compared to controls, even after 
adjusting for smoking [41]. These studies suggest that alterations in lung 
structure/function and composition precede the development of lung cancer, which 
posits one to consider that the normal, healthy lung is able to successfully defend 
itself against genomic alterations due to genetic mutations.  
Lung tissue remodeling can be defined as alterations in the composition and 
deposition of extracellular matrix (ECM) proteins. While the ECM plays roles 
consistent with the organs in which it is found, it is usually composed of similar 
macromolecules; the fibrous proteins like collagens, fibronectins, laminins, and the 
proteoglycans [42]. These proteins are capable of self-assembling into elaborate 
and extensive, interconnected three-dimensional networks that have several roles. 
The ECM provides structural support for tissues, acting as a glue and/or scaffold 
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that holds cells together, but it is also has regulatory and functional roles that 
determine cell shape, activity, and differentiation [43]. It is thus crucial in 
maintaining tissue homeostasis. It is not surprising then that alterations in the ECM 
(i.e. lung tissue remodeling) have been linked with several diseases. For example, 
Ehlers-Danlos syndrome, an inherited disease marked by joint, skin, and blood 
vessel problems, is caused by mutations in one or more genes that results in 
defects in processing and structure of collagen. Additionally, Marfan’s syndrome is 
caused by an absence of fibrillin, which leads to a lack of elastic recoil in the aorta, 
predisposing individuals who suffer from this disease to aortic rupture.  In terms of 
the lung, tissue remodeling is one of the key features of both COPD and IPF, 
diseases that are distinct, and yet that share many similarities [44,45]. For 
example, in IPF, one of the main problems is excessive collagen type 1 deposition, 
mainly caused by increased TGFb signaling, which leads to impaired gas 
exchange [46,47]. This is also true of COPD, where ECM composition in the airway 
wall has been shown to be altered compared to normal, healthy subjects [44,48]. 
While excessive collagen deposition is hallmark of tissue remodeling, fibronectins 
are also present in large quantities in areas of fibrosis [49] and tissue repair/wound 
healing [50,51]. Interestingly, alterations of the ECM have also been shown to 
occur with aging, with chronic inflammation and/or oxidative stress suggested as 
the possible cause [52].  
Thus, while lung tissue remodeling is characteristic of COPD and IPF, both 
risk factors for lung cancer, the true role that lung issue remodeling plays in lung 
cancer remains undefined and further research in this area is warranted.  
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1.5 Fibroblasts  
 Fibroblasts were first identified in the late 1800’s by their location and 
appearance [53,54], and yet they remain poorly defined in molecular terms. They 
are usually identified by their elongated, spindle-shaped appearance. While certain 
markers in the literature are used to identify fibroblasts, there are none to date that 
are known to be exclusive to fibroblasts, and there is a large variation in fibroblasts 
isolated from different anatomical areas of the body. For example, desmin appears 
to be a good marker for identifying fibroblasts isolated from the skin, while 
discoidin-domain receptor 2 can be used to identify cardiac fibroblasts [55,56].  
 Fibroblasts are the predominant cell type of tissue stroma. In normal tissue 
homeostasis, they are largely responsible for the production and function of the 
ECM, in which they are embedded. The ECM, as described previously, functions 
as a scaffold that holds cells together, but also has regulatory and functional roles 
that determine cell shape and activity. Thus, fibroblasts are key players in tissue 
remodeling, and have prominent roles in the development and progression of 
COPD and IPF. Increased TGFb signaling is a main driver of tissue remodeling 
that has proven difficult to target in diseased states due to the roles of TGFb in the 
functioning of normal cells. However, it has recently been reported that specific 
inhibition of TGFb signaling in lung fibroblasts could inhibit lung and tumor fibrosis 
[57]. As key drivers of the development and progression of COPF and IPF, both 
risk factors for lung cancer, fibroblasts also play roles in lung cancer progression 
although the exacts roles and mechanisms are undefined, with contradictory 
reports in the literature. For example, Yamauchi et al., showed that TIG-3 
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fibroblasts, when co-implanted with lung cancer cells, increased tumor growth at 
the site of injection and metastases to the lung, and that this effect was due, at 
least partly, to TGFb-mediated interactions [58]. These experiments, however, 
were performed in NOG mice, which are highly immunodeficient and thus must be 
interpreted carefully. In contrast, others have shown that normal lung fibroblasts 
play a role in inhibiting lung cancer progression. For example, Mishra et al., 
showed significantly fewer metastatic lesions in an ex vivo 4D acellular lung model 
when H460 cells were seeded with normal lung fibroblasts compared to 
carcinoma-associated fibroblasts (CAFs) [59]. These data, among others, point to 
the complicated nature of tumor-stromal cell interactions, and warrant further 
research in this area, particular in the lung. 
 
1.6 Fibronectin 
 Fibronectin is a large, ubiquitously expressed, multi-domain glycoprotein 
located primarily in extracellular fluids, connective tissues and on many cell 
surfaces. It exists in the body in two forms: a circulating, soluble dimer form 
produced mainly by hepatocytes and found in the plasma [60] (referred to as 
“plasma fibronectin”) and an insoluble form produced by fibroblasts and other cells 
(referred to as “cellular fibronectin”) that is embedded in fibrils in the ECM [61]. 
One crucial feature that distinguishes these two forms from each other is 
accomplished by alternative splicing and is characterized by the inclusion of at 
least one of two extra exons termed Extra Domain A (EDA) and/or Extra Domain 
B (EDB) [62–64]. One or both of these domains are present in cellular fibronectin 
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(cFN), but absent in plasma fibronectin (pFN). While the primary structure and 
alternative splicing of fibronectin has been known for decades, the specific 
functions of these isoforms have been difficult to study in vivo until recently, when 
animals lacking these isoforms were developed.  
 Fibronectin itself plays a crucial role in embryogenesis and lung 
development, evidenced by its high expression in embryonic tissues and by the 
fact that animals lacking fibronectin are embryonic lethal [65,66]. Fibronectin has 
roles in several cellular processes, such as hemostasis, wound healing, and host 
defense. One of its most basic functions in these instances is in promoting 
adhesion to and the spreading of cells on various solid substrates, such as, 
collagen, fibrin, and gelatin [67–70]. For example, during wound healing, pFN exits 
the damaged blood vessels, and together with other molecules and cells (e.g. fibrin 
and platelets), forms a hemostatic plug that serves as a scaffold or net that 
supports cell migration and re-epithelialization. Mice lacking pFN however, are still 
able to heal skin wounds [71], while mice lacking fibronectin EDA are not [72], 
suggesting that fibronectin EDA produced locally at the site of injury is sufficient 
for wound healing. Although fibronectin has been shown to have roles in normal 
wound healing, excessive fibronectin levels have been shown to promote disrepair 
[36]. 
 More recently, fibronectin has been implicated in several types of cancer 
[73,74]. While fibronectin EDA has been shown to be a vascular marker for solid 
tumors and metastases of the liver [75], and immunization against fibronectin EDA 
in a therapeutic setting has been shown to decrease tumor burden and lung 
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metastases in the MMTV-PyMT transgenic model of metastatic mammary 
carcinoma [76], little is known about its role in cancer and more specifically lung 
cancer.  
 
1.7 Oxidative Stress  
 The term “oxidative stress” was first proposed by Helmut Sies in 1985 as “a 
disturbance in the pro-oxidant–antioxidant balance in favor of the former” [77]. This 
disturbance can be due to high levels of oxidants, or low levels of antioxidants. 
This definition has been useful and has led to the discovery of a number of 
diseases that are associated with oxidative stress, such as cancer, diabetes, and 
neurodegeneration. The main drivers of oxidative stress in these instances are 
superoxide anion, hydrogen peroxide, and the hydroxyl radical, collectively termed 
reactive oxygen species (ROS). There are a variety of sources of ROS in the body: 
NADPH oxidases, cytokine and growth factor receptors, the electron transport 
chain, and phase 2 drug metabolizing enzymes, such as xanthine oxidases and 
cytochrome p450s, among others. ROS can cause reversible modifications to 
protein side chains on methionine and cysteine residues. These have important 
regulatory and signaling functions in the body. However, ROS can also cause 
irreversible damage to macromolecules, so the body contains numerous 
enzymatic (glutathione and thioredoxin) and non-enzymatic (catalase, superoxide 
dismutase, glutathione peroxidase) cellular defenses to protect against these 
deleterious effects. Many of these defenses are thiol-dependent. As such, 
oxidative stress can now be quantified in humans as the redox state of plasma 
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glutathione/glutathione disulfide (Eh GSH/GSSG) and plasma cysteine/cystine (Eh 
CyS/CySS). These thiol/disulfide couples becomes oxidized with age [78], in 
response to smoking, and in various diseases [79]. However, we now know that 
plasma GSH redox is not in equilibrium with thioredoxin-1 or the larger 
cysteine/cystine (Cys/CySS) pool. These systems also respond differently to 
physiologic and chemical stimuli. These data, along with the inconsistencies of 
several antioxidant trials [80–83] indicate that oxidative stress cannot be defined 
by a single entity, suggesting we need to redefine the term oxidative stress. Dean 
Jones at Emory University has done just that and has proposed a new definition 
of oxidative stress as “a disruption of redox signaling and control.” [84]  This 
definition should redirect our efforts to identify key alterations in redox signaling in 
oxidative stress-related diseases that will then lead to new targets for treatment.  
 Jones has also shown that the physiological redox potential of Cys/CySS 
found in the plasma of healthy subjects is around -80 mV. In aged individuals, and 
those with disease, this redox potential may be oxidized to values between -62 to 
-20 mV. Our lab has previously shown that this type of oxidant stress promotes 
lung fibroblast proliferation, myofibroblast transdifferentiation, and increased 
expression of TGFβ in vitro [85], all of which act to create a pro-fibrotic phenotype 
in the lung. These observations suggest that oxidant stress could act to create an 
oncogenic microenvironment, that renders the aging host susceptible to lung 





 The National Institutes of Health (NIH) recently (June 2015) released a 
Guide notice (NOT-OD-15-102) indicating that researchers should consider sex a 
biologic variable in their studies. A quick literature review will reveal that prior to 
2015, methodology detailing sex and age of most animal studies is severely 
lacking. Moreover, males have been the predominant sex used in animal models 
of biomedical research [86]. This has serious implications for health-care in both 
men and women, as animal models in research are the predominant basis for 
human clinical trials. This is unfortunate, as sex in both animals and humans has 
been shown to be a determining factor in several outcomes of disease. For 
example, Alzheimer’s disease and osteoporosis are more prevalent in women than 
men [87,88]. In terms of pulmonary diseases, mortality from COPD in females 
surpassed that of males in the year 2000 for the first time, likely due to the 
increased number of females who smoke [89]. However, females do appear to be 
at a greater risk of the harmful effects of tobacco smoke, when compared to males, 
although this has only recently begun to be investigated [90]. Interestingly, of the 
5-12% of non-smokers who are diagnosed with COPD, the vast majority are also 
female [91]. These sex differences in pulmonary diseases are also observed in 
several animal models. For example, in a murine model of pulmonary fibrosis, 
while no differences were observed in fibrotic development, males were found to 
have higher basal static lung compliance compared to females, and a significant 
decline in static compliance after bleomycin instillation [92]. In rats, females were 
more susceptible to mortality and fibrotic development, determined by collagen 
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deposition, when compared to males [93]. This effect was abolished in 
ovariectomized females without hormone replacement, and was rescued in 
females given estradiol, suggesting an important role for sex hormones in the 
development of pulmonary fibrosis. In contrast, female mice were found to develop 
less fibrosis, as determined by hydroxyproline content, in a silica-induced lung 
fibrosis model, when compared to males. This effect was again abolished in 
ovariectomized females [94].  
 Among cancers, it is well known and descriptive epidemiological studies 
have shown, that males are more prone to develop cancers, when compared to 
females [95,96]. This is also true for childhood cancers, where prognosis is worse 
for boys than for girls [97]. Additionally, boys who have survived cancer are at a 
greater risk of secondary malignancies [98]. Among lung cancers, it has been 
noted previously, that historically, men were shown to have a higher incidence rate, 
but this was due to a higher frequency of smoking. It now appears that women are 
actually at a greater risk of developing lung cancer compared to males [99]. For 
example, women have been shown to be more susceptible to tobacco carcinogens 
compared to males [100]. Although it appears that women are at a greater risk of 
developing lung cancer in both smokers and nonsmokers, it has been argued that 
among nonsmokers, the increased incidence among women is skewed due to a 






 Taken together, these data portray that population aging in the US and 
worldwide is a matter of great concern and one that simply cannot be ignored. 
NCDs (for the purpose of this dissertation, specifically lung cancer, IPF, and 
COPD) occur almost exclusively in the elderly. Moreover, the vast majority of lung 
cancers, the leading cause of cancer death in the US, also occur in the elderly and 
frequently in individuals with COPD and/or IPF, diseases marked by 
inflammation/tissue remodeling and oxidation of both Eh Cys/CySS and Eh 
GSH/GSSG. Tissue remodeling in the elderly is marked by alterations in the 
composition and deposition of extracellular matrix proteins, including fibronectin 
and one of its splicing variants fibronectin EDA, which has also been shown to be 
increased with aging. This dissertation explores how aging and tissue remodeling 
act in concert to render the host susceptible to lung cancer progression. As the 
main source of fibronectin and fibronectin EDA, we also examined what role 
fibroblasts of the lung play. Finally, we examined the role of sex and oxidative 
stress.  These data led to the development of the following hypothesis:  While 
smoking and other environmental exposures can lead to lung cancer development 
in a genetically susceptible individual, increased oxidation of the Eh Cys/CySS in 
the aging lung creates an oncogenic microenvironment, specifically by increased 
fibronectin EDA levels, that renders the host susceptible to lung cancer 




Figure 1. Dissertation Hypothesis 
While smoking and other environmental exposures can lead to lung cancer 
development in a genetically susceptible individual, we hypothesized that 
increased oxidation of the Eh Cys/CySS in the aging lung creates an oncogenic 
microenvironment, specifically by increased fibronectin EDA levels, that renders 
the host susceptible to lung cancer progression. These events could be 


















ROLE OF AGING AND TISSUE REMODELING IN LUNG CANCER 
 
2.1 Introduction 
Cancer develops most commonly in the elderly with 78% of cancers 
occurring in patients over 55 years of age  [102]. This is also the case for lung 
cancer, which remains the leading cause of cancer death in men and women in 
the US and worldwide  [2]. How exactly aging promotes cancer is unclear, but 
compared to young individuals, aging is characterized by oxidant stress, 
mitochondrial dysfunction, immunologic deficiencies, stem cell exhaustion, and 
accumulation of damage in cells, tissues, and organs, among other things  [103–
106]. Aging has also been characterized by a reduced capacity to respond to 
environmental injury [107]. Yet, exactly how these processes contribute to 
carcinogenesis is unknown.  Interestingly, most lung cancers occur in individuals 
with chronic lung disorders characterized by inflammation and tissue remodeling 
such as COPD and IPF [108]. Considering the emerging data linking inflammation 
and the tumor microenvironment in cancer development and progression [109], it 
is not surprising that lung cancer develops most commonly in such settings.
Since the discovery of the first oncogene, Src, in 1970, and later of cellular 
proto-oncogenes, the prevailing paradigm of cancer development for decades was 
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that cancer arises due to mutations in oncogenes and tumor suppressor genes of 
single cells. However, numerous studies performed in vitro and in vivo have now 
shown that, despite malignant cell transformation, tumor growth is dependent on 
processes such as inflammation and angiogenesis in the microenvironment. In 
fact, it has been shown that a malignant phenotype can be reversed by using 
integrin blocking antibodies [110,111]. Thus, it can be said that genetic mutations 
are necessary, but not sufficient, to cause tumor growth  [7]. It has been known for 
some time that chronic inflammatory diseases such as COPD, asbestosis and 
silicosis increase the risk of lung cancer  [112]. For example, exposure to asbestos, 
and the resulting inflammatory response, have been linked to lung cancer and 
mesothelioma [113]. Indeed, a link between chronic inflammation and many 
cancers is now well established [114] and several studies have demonstrated a 
protective effect of non-steroidal anti-inflammatory drugs in cancer development  
[115]. Others have found that the ability of Rous sarcoma virus to form tumors in 
newly hatched chicks is dependent upon wounding and inflammation, and that the 
pro-fibrotic growth factor, transforming growth factor b (TGFb), can replace 
wounding as a promoter of tumor development [116].  
Despite the above, the contribution of chronic tissue inflammation and 
remodeling and their interaction in lung cancer have been difficult to study in 
humans considering the many confounding factors present, not the least of which 
is exposure to tobacco, perhaps the best known pro-oncogenic agent.  It is for this 
reason that scientists have turned their attention to experimental models of lung 
cancer which, even though they do not exactly resemble the human condition, they 
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allow for the more careful exploration of the role of individual factors.  We 
hypothesized that aging and tissue inflammation/remodeling act in concert to 
promote lung cancer progression, and set out to test this in a syngeneic model of 
lung cancer.  For this, we used aged mice, which have been shown to display 
alterations in inflammatory and tissue remodeling markers  [117].  Aged lungs are 
characterized by, among other things, increased mRNA expression for TGFb, 
matrix metalloproteinases, plasminogen activator inhibitor-1, and matrix molecules 
fibronectin and collagen I  [36,118].  These changes explain, at least in part, the 
alterations observed in the structure of the aging lung. 
One of the matrix molecules upregulated in the setting of aging is a 
fibronectin splicing variant, which is characterized by the inclusion of an extra exon 
termed Extra Type III Domain A (EDA). This is intriguing considering that data 
generated over the past three decades have linked fibronectin with cancers 
including breast, prostate, liver, and lung  [119–121].  However, it has been difficult 
to study the role of fibronectin in vivo mainly because animals with knockout 
mutations in fibronectin are embryonic lethal  [122].  More recently, animals with 
knockout mutations targeting fibronectin EDA were generated and their 
investigation suggests a role for this molecule in wound healing and aging [72].  
Moreover, fibronectin EDA has been linked to lung inflammation and remodeling 
since its deletion is protective in the bleomycin model of lung injury and repair  
[123].  Considering these observations, we also tested animals lacking fibronectin 
EDA. 
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Our studies revealed that aged lungs were more susceptible to metastasis when 
compared to young lungs.  Importantly, studies in young and aged animals 
exposed to bleomycin suggest that tissue remodeling/inflammation augment 
pulmonary metastasis, but only in the aging lung and not in the young lung. The 
effect of bleomycin was abolished in studies performed in fibronectin EDA KO 
mice, despite the presence of fibrosis. Together, these observations suggest an 
interplay between lung aging and inflammation/remodeling in tumor progression, 
and that fibronectin EDA is an important molecule in this setting.  
 
2.2 Materials and Methods 
2.2.1 Reagents and Cell Culture  
Lewis Lung Carcinoma (LLC) cells were purchased from ATCC (CRL-1642; 
ATCC, Rockville, MD) and grown in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceburg, GA) at 37 ºC in a 
humidified 5% CO2 incubator. Cells were used within 3 months of resuscitation. 
Bleomycin (catalog #8416) and cellular fibronectin (cFN; catalog #F2518) were 
purchased from Sigma (St. Louis, MO). Sutures for surgery were purchased from 
Ethicon (catalog #K833).  
 
2.2.2 Young and Aged Animals  
C57BL/6 and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice 
were obtained from Jackson Laboratories and housed in pathogen-free facility at 
the University of Louisville (Louisville, KY), with access to food and water ad 
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libitum. Fibronectin EDA knockout mice were obtained from Dr. Eric White 
(University of Michigan) and verified by PCR analysis and sequencing. All 
experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Louisville.  
 
2.2.3 LLC Model of Lung Cancer  
LLC cells were split 24 hours prior to injections and were harvested in 
growth phase. LLC cells were injected (1E6/100 μL sterile PBS) subcutaneously 
into the hind flank of mice. In parallel experiments, animals were injected with LLC 
cells intravenously (1E5 /100μL sterile PBS). Afterwards, tumors were monitored 
and the length, width, and height, measured weekly, using digital calipers. A tumor 
size >15mm in any direction was considered the endpoint, per IACUC regulations. 
All animals were then sacrificed and tissues were harvested for analysis. The same 
procedure and number of cell were performed for injections into NSG mice. 
 
2.2.4 Bleomycin Model of Lung Injury and Repair  
Bleomycin sulfate was reconstituted in sterile PBS at 1 mU/g of body weight. 
Animals were anesthetized by using a mixture of ketamine and xylazine. Under 
aseptic technique, the neck of the mouse was dissected and the trachea was 
visualized. Bleomycin or PBS was instilled in the trachea, using a 27G needle, in 
a total volume of 40 μL. The wound was sutured with black braided silk and animals 
were monitored and allowed to recover on a heated pad.  
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2.2.5 Tissue Processing and Histological Analysis  
Per IACUC regulations, once subcutaneous tumors reached a size of 15 
mm in any direction, all animals were sacrificed by CO2 administration in a closed 
chamber. Lungs were flushed with PBS, inflated at standard pressure with 
formalin, removed, and formalin-fixed for 48 hours. Lungs were then processed 
through increasing ethanol solutions in an STP 120 Spin Tissue Processor 
(ThermoFisher Scientific, Waltham, MA), paraffin-embedded, and sectioned (6 
μm) using a JUNG RM2055 microtome (Leica, Buffalo Groce, IL). Lung sections 
were then transferred onto charged, glass Colorfrost microslides (VWR Sciences, 
Radnor, PA) for histological analysis. Sections were deparaffinized, rehydrated, 
and stained with hematoxylin and eosin (HE) to evaluate lung tumors, or Masson’s 
trichrome (American MasterTech, catalog #KTMTR2PT) to evaluate collagen 
content for lung fibrosis determination. Five blinded reviewers used the semi-
quantitative Ashcroft scoring scale to score pulmonary fibrosis [124]. 
 
2.2.6 Wound Healing (Scratch Assay)  
LLC cells (2.5E5) were plated in 24-well plates coated with cellular 
fibronectin (10μg/mL) or plastic alone for 24 hours. A scratch was then created 
using a 1 mL pipette tip. Media (2 mL) was then replaced and photographs taken 
at 0 and 24 hours using an EVOSTM XL Core Cell Imaging System (AMG).  
Quantification was performed using ImageJ software by measuring the distance of 
the scratch in 6 separate locations at 0 and 24 hours.  
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2.2.7 Analysis of Data  
Means plus standard deviations of the mean were calculated for all experimental 
values. Significance was assessed by using the Student's t test.  
 
2.3 Results 
2.3.1 Aging is associated with increased lung metastases 
While studying a syngeneic model of lung cancer, we noticed a significant 
variability in the development of lung metastasis.  A retrospective analysis of the 
data revealed that the age of the animals represented an important variable (not 
shown).  To test the role of aging prospectively, wildtype C57BL/6 mice at ages 
3,5,7,9 and 12 months of age were injected subcutaneously with 1E6 LLC cells.  
Tumor growth was followed until tumors reached a size of ≥15 mm, after which 
time, all animals were sacrificed and lungs harvested and formalin fixed.  As 
depicted in Fig. 2A and 2B, mice failed to develop lung metastases until 7 months 
of age or older. We observed small differences in the size of the primary tumors, 
but these were not statistically significant (not shown).   
To circumvent the potential confounding effects of skin immunity, we 
repeated similar experiments in animals injected intravenously with the tumor cells.  
In these experiments, we observed that only 50% of young (~3.5 months) mice 
developed lung tumors compared to 100% of old (~12 months) mice (Fig. 2C).  
Aged mice also developed a greater number of lung tumors when compared to the 
number of tumors developed in the few affected young mice (Fig. 2D). Thus, aged 





Figure 2. Aging is Associated with Increased Lung Metastases	
(A,B)  WT C57BL/6 mice, ages 3, 5, 7, 9 and 12 months old were injected with 
1E6 WT LLC cells into the hindflank. Per IACUC regulations of endpoints, tumor 
formation and size were followed until a tumor size of ≥15 mm in length or width 
was established. All mice were then sacrificed and lungs harvested and processed 
for examination of metastases. All mice developed tumors at the site of injection, 
with no differences in size observed at day 17. (A) Percentage of mice in each 
group where lung metastases were identified. (B) Number of lung metastases in 
each animal in each group. (C,D) Young (3.5 months) and aged (12 months) WT 
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at day 13. (C) Percentage of mice in each group where lung tumors were 
identified. (D) Number of intravenous lung tumors in each animal in each group. 
Aged mice developed more tumors in the lung (6.3 +/- 3.4) compared to young 




















2.3.2 Bleomycin treatment is associated with increased metastases, but only 
in aged lungs 
To examine the role of lung inflammation/remodeling in lung cancer 
progression, young (~3.5 months) and aged (~9.5 months) animals were instilled 
with bleomycin (1mU/g BW) followed by injection of LLC cells 14 days after 
bleomycin treatment. As expected, bleomycin induced weight loss (Fig. 3A) and 
lung inflammation/remodeling (Fig. 3B) in both young and aging mice.  In animals 
injected with LLC cells after bleomycin treatment, we again observed small 
differences in the size of subcutaneous tumors at the time of euthanasia, but these 
were not statistically significant (data not shown).  However, interestingly, 
bleomycin augmented the number of lung metastases in the aged murine lungs, 
but not in young lungs (Fig. 3C), despite the presence of inflammation/remodeling 















Figure 3. Bleomycin Treatment is Associated with Increased Metastases, but 
Only in Aged Lungs 
Young (~3.5 months) and aged (~9.5 months) WT C57BL/6 mice were instilled 
intratracheally with PBS (young, n=7; aged, n=8) or bleomycin (Bleo; young, n=7; 
aged, n=7). At day 14, 1E6 LLC cells were injected subcutaneously into the 
hindflank. (A) Change in weight in aged mice is shown. Bleomycin significantly 
induced weight loss in all mice at day 14 and day 21 post-instillation. There were 
no statistically significant differences in weight loss between young and aged mice. 
Mice instilled with PBS did not experience weight loss. (B) Representative HE 










































metastases are observed in all images (indicated by arrows), while fibrosis is 
readily apparent in the bleomycin treated lungs. (C) Number of lung metastases in 
aged mice are shown. Young mice failed to develop lung metastases in either 
group, while bleomycin instillation in aged mice increased the number of lung 


















2.3.3 Fibronectin EDA is dispensable for aged-related lung cancer 
progression, but required for bleomycin-induced augmentation of 
metastasis 
Since aged lungs show alterations in the expression of fibronectin EDA, and 
fibronectin is implicated in carcinogenesis, we hypothesized that this matrix 
molecule contributes to the aging effect.  To test this, untreated aged wildtype and 
aged fibronectin EDA knockout mice were injected with LLC cells, both 
subcutaneously and intravenously. For subcutaneous tumors, growth was followed 
until tumors reached a size of ≥15mm, after which time, all animals were sacrificed 
and lungs harvested and formalin fixed. In the subcutaneous model, no differences 
were observed in the growth of the primary tumor (data not shown) or in the 
number of lung metastases (Fig. 4A) when comparing aged wildtype and aged 
fibronectin EDA knockout animals. Likewise, when animals were injected 
intravenously, no differences were observed in the number of lung tumors when 
comparing aged wildtype and aged fibronectin EDA knockout animals (Fig. 4B). 
Thus, despite being increased in aged lungs and being implicated in 
carcinogenesis and cancer progression, the absence of fibronectin EDA did not 
inhibit cancer progression in aged lungs in the LLC model. 
To test the role of fibronectin EDA in cancer progression in the setting of 
tissue remodeling/inflammation, we repeated experiments with bleomycin in aged 
fibronectin EDA KO animals. Although others have reported fibronectin EDA to be 
essential for the development of lung fibrosis in the bleomycin model [123], we 
observed no differences in the development of bleomycin-induced fibrosis in WT  
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Figure 4. Fibronectin EDA is Dispensable for Age-Related Lung Cancer 
Progression  
WT C57BL/6 and FN EDA KO mice were injected with 1E6 WT LLC cells into the 
hindflank or 1E5 LLC intravenously.   (A) Number of metastases in young WT (~2.5 
months, n=5) and EDA KO (2 months, n=3) mice and in aged WT (10 months, n=5) 
and EDA KO (10 months, n=3) mice. Young mice in both groups failed to develop 
metastases. There were no statistically significant differences in the number of 
metastases between aged WT (1.6 +/- 1.1) and aged EDA KO (4.3 +/- 4.2) 
mice. (B) Number of intravenous lung tumors in aged WT and EDA KO mice are 
shown. There were no statistically significant differences in the number of lung 
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and fibronectin EDA KO mice (Fig. 5A and 5B). However, interestingly, when 
injected with LLC cells, the augmentation of pulmonary metastases due to 
bleomycin was abolished in fibronectin EDA KO mice (Fig. 5C). 
Considering the above, we hypothesized that fibronectin EDA provides a 
scaffold for the proliferation, migration and organization of tumor cells within 
remodeled lung tissue. This is consistent with data showing that over 75% of tumor 
cells metastasizing to the lung co-localized to areas of inflammation/fibrosis (Fig. 
6A and 6B). Consistent with this, LLC migration was increased on plates coated 
with cellular fibronectin compared to plastic (Fig. 7A-B), and LLC proliferation was 

















Figure 5. Fibronectin EDA is Required for Bleomycin-Induced Augmentation 
of Metastasis  
WT C57BL/6 (~10 months) and FN EDA KO (~9 months) mice were instilled 
intratracheally with PBS or bleomycin. At day 14, 1E6 LLC cells were injected 
subcutaneously into the hindflank. (A) Ashcroft scores of 5 blinded reviewers. (B) 
Representative trichrome stained images at 4x magnification depict lung fibrosis 
of varying severity in both bleomycin treated WT and EDA KO mice. (C) Number 
of lung metastases in aged mice are shown. Bleomycin increased the number of 
lung metastases in WT mice (12.1 +/- 10.0 vs 33.7 +/- 8.6, ***P<.001) but not in 
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Figure 6. Lung Metastases Develop Primarily in Fibrotic Areas 
Paraffin embedded sections from WT C57BL/6 mice from figure 5C were stained 
with Masson’s Trichrome. (A) Representative Masson’s Trichrome stained images 
at .4x and 4x magnification depict prominent lung fibrosis and LLC metastases 
(green circles). (B) Percentage of LLC metastases in areas of lung fibrosis in each 
individual mouse. The % of metastases that developed in fibrotic areas was greater 





































Figure 7. Effect of cFN on LLC Proliferation and Migration 
(A) LLC cells were plated on plastic or cellular fibronectin (cFN; 10µg/mL) coated 
24-wellplates. (B) After 24 hours 59.1 +/- 3.2% of the initial wound area remained 
on plastic vs 26.9 +/- 2.7% on cFN. *** P<.001. (C) LLC cells were plated in 48-















































































2.3.4 Role of Immunity 
Finally, we wanted to test the role of immunity in our model to examine if it 
mediated the age-related effect on lung metastasis.  For this, we injected LLC cells 
into young and aged NOD scid gamma (NSG) mice, which are extremely 
immunodeficient, lacking B and T cells, as well as functional NK cells. Both young 
and aged mice developed tumors at the site of injection within 2 weeks, although 
no differences were observed between the groups when the animals were 
sacrificed at day 17 (Fig. 8A).  Although the number of metastases to the lung was 
greater in the aged mice, this was not statistically significant (Fig. 8B). However, 
aged NSG mice developed larger metastases to the lung compared to young NGS 
mice (Fig. 8C-D). The location of the lung metastases in the NSG mice also 
differed from those observed in WT animals. While metastases in WT mice 
developed in areas adjacent to blood vessels, this was not the case in NSG mice, 
where the majority of metastases developed in the periphery of the lung (Fig 9). 
These data suggest a role for innate immunity in tumor progression beyond the 
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Figure 8. Effect of Immunity on Lung Cancer Progression 
(A-C) Young (2 months) and Aged (9 months) NSG mice were injected 
subcutaneously into the hindflank with 1E6 LLC cells, and followed for tumor 
formation. Aged WT C57Bl/6 mice were used as a third group as a positive control. 
Mice were sacrificed at day 17 and lungs removed and processed for examination 
of metastasis. There were no differences between groups in tumor volume at the 
site of injection (A), or the number of metastases to the lung (B). Although the 
number of metastases to the lung between groups was statistically unchanged, 
aged NSG mice developed larger metastases (in size) to the lung (C). Graph 

















Figure 9. LLC Metastases in WT and NSG Mice 
Female WT C57BL/6 and female NSG mice were injected with LLC cells 
subcutaneously (1E6/100µL PBS) and then followed for tumor progression. A 
tumor size >15mm in any direction was considered the endpoint. Mice were then 
sacrificed and lungs harvested and processed for examination of metastases. 
Representative HE-stained lung images showing lung metastases at 10X are 










By the year 2020, it is estimated that 70% of all neoplasms will occur in 
individuals aged 65 years or older [125]. Among them, lung cancer remains the 
deadliest and occurs most commonly in individuals with chronic lung disorders 
characterized by inflammation and tissue remodeling such as chronic obstructive 
pulmonary disease and fibrosis [108].  The relative contribution of these processes 
to the pathogenesis of lung cancer, especially metastatic disease, has been 
difficult to study in part because of the concomitant exposure to tobacco, a well-
known carcinogen [126]. Thus, we set out to study the role of aging and lung tissue 
inflammation/remodeling in an experimental syngeneic model of lung cancer. 
Several observations were made as summarized below.  
First, we observed that aged lungs develop more metastatic lesions than 
young lungs, resembling the human condition. This was observed when LLC cells 
were injected subcutaneously or intravenously, which suggests that some inherent 
factor(s) in the aged lungs is responsible for this susceptibility, and not tumor 
implantation, growth, or metastasis from the primary tumor, nor does it relate to 
the ability of cancer cells to escape the immune system in the periphery.  These 
data contribute to the notion that malignant cell transformation alone is not 
sufficient for tumor growth and progression. Young, healthy, immunocompetent 
animals are able to mount a successful defense in the lung to protect against lung 
lesions. However, aging appears to render the lung vulnerable to cancer 
progression.  
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Second, we showed that lung tissue inflammation/remodeling was 
associated with increased lung metastases, but only in aged animals suggesting 
an interplay between aging and lung injury. In our hands, bleomycin induces 
fibrosis in both young and aged mice, with aged mice showing greater injury [36]. 
Young mice, however, still failed to develop lung metastases, which suggests that 
inflammation and/or tissue remodeling is not sufficient for cancer progression in 
our model. In light of the fact that aged mice show greater injury in response to 
bleomycin, it remains to be determined if increased inflammation or increased 
fibrosis contributes to the increased susceptibility to lung cancer. Independent of 
its role, the amount of fibrosis detected cannot fully explain the differences 
observed. 
Third, we observed that, even though fibronectin EDA is increased in aging 
lungs and has been implicated in cancer, this matrix molecule was not required for 
cancer progression in normal lungs. Fibronectin EDA has been shown to be a 
vascular marker for solid tumors and metastases [75], and immunization against 
fibronectin EDA in a therapeutic setting has also been recently shown to decrease 
tumor burden and lung metastases in the MMTV-PyMT transgenic model of 
metastatic mammary carcinoma [76]. Based on these observations, we 
hypothesized that the aging lung contains a pro-oncogenic microenvironment due 
to increased levels of fibronectin EDA that renders the host susceptible to lung 
cancer progression.  However, this was not found to be the case in our model. We 
found tumors in lung even in fibronectin EDA knockout mice suggesting that this 
matrix molecule is not required for lung metastasis.  
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Fourth, although fibronectin EDA could not explain the increased 
susceptibility to lung metastasis in the aging lung, it was required for the 
augmentation of lung metastasis in response to tissue injury induced by bleomycin. 
Of interest was the fact that, despite a report in the literature that fibronectin EDA 
is essential for bleomycin induced lung fibrosis, in our hands, fibronectin EDA KO 
mice developed as much bleomycin-induced lung fibrosis as WT animals. This 
might be related to differences in the age of animals used, and dose and batch of 
bleomycin administered. Nevertheless, we did not observe an augmentation of 
lung metastasis in response to bleomycin in fibronectin EDA KO animals, which 
suggests that this matrix molecule plays an important role in lung cancer 
progression in the setting of aging coinciding with tissue remodeling/inflammation. 
Several mechanisms may explain the pro-oncogenic effects of fibronectin EDA as 
it may serve as a scaffold for the proliferation, organization, and migration of tumor 
cells.  
Finally, we observed that both young and aged NSG mice developed 
tumors at the site of injection, and metastases to the lung in the LLC model. 
Although there were a greater number of metastases in the aged NSG mice, this 
was not statistically significant. However, aged NSG mice had larger tumors in 
their lungs compared to young NSG mice. The location of metastases in the NSG 
mice also differed from those observed in WT mice. These data suggest that the 
increased number of metastases observed in aging WT mice is somehow 
dependent on alterations in immune responses involving B, T and NK cell – related 
mechanisms. This could possibly be due to decreased T-cell dependent functions, 
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which have been shown to decline with aging [105,127,128]. This will require 
further investigation.  
Overall, we report that aging acts in concert with lung injury to further 
increase the risk of lung cancer progression.  This work adds to a growing body of 
literature implicating both aging and lung injury as risk factors for lung cancer 
development and progression [129]. While aging is thought to promote lung cancer 
progression through immune-mediated factors, the amplifying effects of lung injury 
in aging appear dependent on fibronectin EDA. These data, along with those of 
Sueblinvong, et al. [36], suggest that young mice are able to successfully repair 
bleomycin-induced lung injury, while old mice are predisposed for disrepair, and 
thus more susceptible to lung cancer progression. Our data suggest that this 
aberrant repair in the aged lung is facilitated by fibronectin EDA, which is not only 
increased in the aging lung, but also increased in the aging lung in response to 
bleomycin, when compared to young lungs. It is important to note that these 
mechanisms may vary in different cancers as aging does not appear to affect 
tumor progression similarly when different tumors are tested [130]. 
Taken together, our data suggest that age-dependent host immune factors 
influence lung cancer progression. Importantly, lung inflammation and tissue 
remodeling augment pulmonary metastasis in the aging lung, but not in young 
lungs, through mechanisms involving fibronectin EDA, which perhaps provides a 
scaffold for tumor cell migration, organization, and proliferation. This points to an 
interplay between lung aging and inflammation/remodeling in lung tumor 
progression. Admittedly, strategies for targeting fibronectin in the clinic would be 
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limited due to the high concentration of fibronectin in the plasma and other organs, 
but much work is being done in this area [131]. Perhaps a better approach would 
be to target fibronectin recognition by blocking its association with its various 
integrins [132]. This report underscores the need for further studies in this area to 




ROLE OF FIBROBLASTS IN LUNG CANCER 
 
3.1 Introduction 
 Although the incidence of lung cancer has decreased over the past decade, 
it still remains higher than that of breast cancer, prostate cancer, and colon cancer 
combined [2], and remains a significant threat worldwide [133]. Tobacco use 
remains the number one risk factor, exposing an individual to a myriad of 
carcinogens, among other harmful compounds [126]. The prevailing paradigm for 
decades has been that cells, when exposed to these and other carcinogens,  
acquire mutations in vital genes that over time lead to the development of tumors 
[134]. However, it is now well-documented that mutations alone are not sufficient 
to account for tumor development and progression [7]. In fact, a decreased 
incidence of colon and breast cancer has been observed through the use of non-
steroidal anti-inflammatory drugs [135,136], which suggests that factors other than 
cellular transformation are needed to cause tumor growth. This concept was first 
proposed in 1889, when Stephen Paget revealed his seed and soil hypothesis, 
which described a non-random pattern of metastasis in which cancer cells 
(“seeds”) depend on crosstalk with the microenvironment (“soil”) for growth and 
progression. In other words, metastasis from a primary tumor to distant organs is 
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site specific, where the soil produces molecular factors appropriate and necessary 
for the seed’s survival. Since then, it has been shown that processes such as 
inflammation, angiogenesis, and paracrine signaling from stromal cells in the tumor 
microenvironment are vitally important for tumors to survive and progress [137].  
Fibroblasts are a predominant cell type in the tissue microenvironment and 
are largely responsible for the production of the extracellular matrix, in which they 
are embedded. Much attention has been given to the role of cancer-associated 
fibroblasts, which have been termed activated fibroblasts, identified by their 
expression of alpha-smooth-muscle actin [138]. It is well-known that these 
activated fibroblasts can promote tumor progression. However, the role that normal 
lung fibroblasts play in the progression of lung cancer has been difficult to 
ascertain, with conflicting reports in the literature. For example, Yamauchi et al., 
showed that TIG-3 fibroblasts, when co-implanted with lung cancer cells, increased 
tumor growth at the site of injection and metastases to the lung, and that this effect 
was due, at least partly, to TGFb-mediated interactions [58]. These experiments, 
however, were performed in NOG mice, which are highly immunodeficient and thus 
must be interpreted carefully. In contrast, others have shown that normal lung 
fibroblasts play a role in inhibiting lung cancer progression. For example, Mishra 
et al., showed significantly fewer metastatic lesions in an ex vivo 4D acellular lung 
model when H460 cells were seeded with normal lung fibroblasts compared to 
carcinoma-associated fibroblasts [59]. Others have shown an important role of 
fibroblast-derived hepatocyte growth factor (HGF) in lung cancer progression 
[139,140]. This has largely been shown in the setting of resistance to epidermal 
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growth factor receptor tyrosine kinase inhibitors [141,142]. These data, among 
others, point to the complicated nature of tumor-stromal cell interactions, and 
warrant further research in this area. Even fewer studies have examined the role 
of young versus aged fibroblasts in terms of lung cancer. With the emerging 
practice of personalized medicine based on a patient’s genetic profile, perhaps the 
conflicting reports in the literature could be explained, at least in part, to differences 
in the genetic profile of the host and/or the various lung cancer cell lines used.   
Here, we attempt to assess the role that normal, untransformed fibroblasts 
of the lung play in lung cancer progression in vitro and in vivo in immunocompetent 
animals using human and murine lung fibroblast and lung cancer cell lines. We 
also explore the effect of aging, by using primary lung fibroblasts isolated from old 
animals.  
 
3.2 Materials and Methods 
3.2.1 Reagents  
Transwell inserts with an 8.0 µm pore size were purchased from Corning 
(Costar, catalog #3464). All chemical reagents were purchased from Tocris 
Bioscience (Ellisville, MO) unless otherwise specified. The cell transformation 
detection assay (colony formation) kit was obtained from Millipore (Temecula, CA, 
catalog #ECM570). The Cell Titer-Glo® Luminescent Cell Viability Assay (catalog 
#G7572) and Caspase-Glo® 3/7 Assay (catalog #G8091) were obtained from 
Promega (Madison, WI). 
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3.2.2 Cell Culture 
Lewis Lung Carcinoma (LLC) (CRL-1642), A549 (CCL-185), H1792 (CRL-
5895), H460 (HTB-177), WI38 (CCL-75), and IMR90 (CCL-186) cells were 
purchased from ATCC (Rockville, MD). Primary murine lung fibroblasts (PLF) were 
isolated by harvesting lungs from 3-month-old (young) or 24-month-old (old) 
C57BL/6 mice. Lungs were minced and allowed to attach to a p100 dish by air 
drying for 5 minutes. Five mL of DMEM were then gently added. All cells were 
grown in DMEM supplemented with 10% FBS, at 37 ºC in a humidified 5% CO2 
incubator. 
 
3.2.3 Fibroblast Conditioned Media 
 Primary murine lung fibroblasts (1.5E6) were plated in p150 dishes in 25 
mL DMEM with 10% FBS, and allowed to grow for 3 days. For controls, 25 mL 
DMEM was added to p150 dishes with no cells and incubated for 3 days. Media 
was then collected from all groups into 50 mL conical tubes and spun at 1000 RPM 
for 5 minutes, filtered (0.2 μM), and then transferred to new 50 mL conical tubes 
and stored at -70ºC until future use. The same protocol was used from IMR90 and 
WI38 fibroblasts, but 1.5E6 and 1E6 cells were plated in p100 dishes in 15 mL 
DMEM, respectively.  
 
3.2.4 Morphology 
 LLC (100/100 µL-well), A549 (1000/100 µL-well), H1792 (1500/100 µL-well) 
and H460 (1000/100 µL-well) cells were plated in clear 96-well plates and cultured 
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in control DMEM or FCM for 5 days. Cells were then formalin fixed by adding warm 
4% paraformaldehyde for 10 minutes. Cells were washed with PBS and 
permeabilized with 1% Triton X-100 (PBS) for 5 minutes. Cells were again washed 
with PBS. Cells were stained with phalloidin for 1 hour at room temperature, 
followed by DAPI staining for 1 minute. Cells were then photographed using an 
EVOSTM FL digital inverted fluorescence microscope (AMG, AMEFC-4302).  
 
3.2.5 Western Blot Analysis 
 For protein isolation, all cells were plated in 6-well plates and incubated 24 
- 120 hours. Some experiments included a 24-hour serum starvation period prior 
to treatment. After treatment, cells were washed with PBS and collected into 1.5mL 
Eppendorf tubes in PBS via scraping. No trypsin was used. Cells were then 
centrifuged at 750 x g and resuspended in homogenization buffer containing 50 
mM NaCl, 50 mM NaF, 50 mM NaP2O7-10 H2O, 5 mM EDTA, 5 mM EGTA, 2 mM 
Na3VO4, 0.5 mM PMSF, 0.01% Triton X-100, 10 mM HEPES, pH 7.4.  Samples 
were placed on ice and then sonicated with 3 quick pulses using a Sonifier 450 
(Branson, Danbury, CT). Protein concentrations were determined using Bradford 
reagent (Sigma) readings in DU-800 Spectrophotometer (Beckman Coulter, Brea, 
CA) in a 96-well format. Protein (20 µg) was mixed with 5X sample buffer and water 
to an equal volume for all samples, heated at 90 ºC for 5 minutes, briefly 
centrifuged, and then loaded into 10-well, 10% SDS polyacrylamide gels (8% for 
FN). Gels were run in a mini trans-blot system (Bio-rad), on ice, at 100-150V for 2 
hours, using a Powerpack HC power supply (Bio-rad). Gels were then soaked in 
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Pierce Transfer Buffer (Thermo Scientific) for 15 minutes. Protein was transferred 
to 0.2 µm Nitrocellulose Membranes (Bio-rad) using a Trans-Blot SD semi-dry 
transfer cell (Bio-rad) at 25V for 1.5 hours. Membranes were then air dried for 15 
minutes and blocked for 1 hour at RT in Odyssey Blocking Buffer (PBS, Li-Cor). 
Membranes were then incubated overnight at 4ºC with the primary antibodies 
against GAPDH (Sigma; 1:10,000), fibronectin (Sigma, 1:1000), e-cadherin (Cell-
Signaling, 1:500), vimentin (Cell-Signaling, 1:500), alpha smooth muscle actin 
(Abcam, 1:1000). Membranes were washed (3 x 10 minutes) with PBST and then 
incubated with the appropriate secondary antibody (1:20,000) for 1 hour at RT. 
Membranes were again washed in PBST (3 x 10 minutes). Florescent blots were 
then scanned on a LI-COR Odyssey CLx imaging system and analyzed in Image 
Studio (LI-COR). 
 
3.2.6 Proliferation Assay 
 LLC (100/500 µL-well), A549 (1000/500 µL-well), H1792 (1500/500 µL-well) 
and H460 (1000/500 µL-well) cells were plated in clear 48-well plates and cultured 
in control DMEM or FCM, and allowed to grow up to 7 days. Media was replaced 
every 2-3 days. Cell proliferation was then evaluated using the CellTiter-Glo® 
Luminescent Cell Viability Assay. Briefly, media was aspirated and 100µL 
CellTiter-Glo lysis buffer was added. Plates were shaken for 1 minute, incubated 
for 8 minutes at room temperature, and then shaken an additional minute. Seventy-
five µL was then transferred to an all-white 96-well plate and read using a 
Luminoskan Ascent Luminometer (Beckman Coulter).  
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3.2.7 Transwell Migration Assay 
 LLC, A549, H1792, and H460 cells (all at 50,000/200 µL) were plated into 
Transwell inserts in 200 µL serum free DMEM in 24-well plates. Complete DMEM 
or FCM (700 µL) was pipetted into the bottom of the well to act as a 
chemoattractant. Inserts were removed 16 hours later (24 hours for LLC cells) and 
cells were fixed and stained using Thermo Scientific’s Kwik-Diff kit (catalog 
#9990700), per the manufacturer’s instructions. Inserts were then rinsed in dH2O 
and non-adherent cells on the inside of the insert were removed with a cotton 
swab. Cells were then photographed using an EVOSTM XL Core Cell Imaging 
System (AMG).  
 
3.2.8 Colony Formation Assay 
The colony formation assay was performed according to Millipore’s 
instructions (Cell Transformation Detection Assay, ECM570). Briefly, a 0.8% base 
agar layer was prepared (500 μL/24-well) by boiling the agar in dH2O and allowed 
to cool for 5 minutes. An equal amount of DMEM was then added and plated out.  
Plates were placed at 4ºC for at least 30 min to allow the base agar layer to gel. 
The top agar (0.4%) layer (200µL) was prepared by mixing 0.8% solution with 
equal amount of culture media. Plates were incubated at 37ºC for 5 minutes prior 
to addition of cells (500-1000/well) followed by incubation for up to 21 days. Control 
media or FCM (250 μl/well) was added and then replaced every 3-4 days, after 
aspiration of old media. Afterwards, colonies were photographed and counted 
using ImageJ software. 
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3.2.9 Wound Healing (Scratch) Assay 
 LLC (5E5/5 mL DMEM), A549 (7.5E5/5 mL DMEM), H1792 cells (1E6/5 
mL DMEM) and H460 cells (1E6/5 mL DMEM) were plated into 6-well plates. 
After 24 hours, cells were scratched with a sterile 1 mL pipette tip. Media was 
then aspirated and replaced with 5 mL control DMEM or FCM. Media was 
replaced at 24 hours. Photographs were taken at 0 and 48 hours using an 
EVOSTM XL Core Cell Imaging System (AMG). Quantification was accomplished 
using ImageJ software, by measuring the distance of the scratch area in three 
separate locations at 0 and 48 hours. 
 
3.2.10 Caspase 3/7 Activation Assay 
 LLC (3000/100 µL-well), A549 (5000/100 µL-well), H1792 (5000/100 µL-
well) and H460 (5000/100 µL-well) cells were plated in white-walled, clear-
bottom, 96-well plates and cultured in control DMEM or FCM for 24 hours. Media 
was then aspirated and 50 µL of control DMEM or FCM with or without cisplatin 
was added. Final concentrations of cisplatin were 10, 30, 30 and 100 µM for LLC, 
A549, H460 and H1792, respectively. Apoptosis was then evaluated using the 
Caspase-Glo® 3/7 Assay. Briefly, 50 µL Caspase-Glo® lysis buffer was added. 
Plates were shaken for 2 minutes, incubated for 1 hour at RT, shaken an 
additional 2 minutes, and then read using a Luminoskan Ascent Luminometer 
(Beckman Coulter). Cell viability was evaluated using the CellTiter-Glo® 
Luminescent Cell Viability Assay as described above. 
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3.2.11 Animal Studies 
All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Louisville.  LLC cells and primary lung fibroblasts 
were plated out 24 hours prior to injections and were harvested at ~50% 
confluence to ensure cells were in growth phase.  LLC cells (1E6 /100 μl sterile 
PBS) were injected alone or together with primary lung fibroblasts (1E6 /100 μl 
sterile PBS) subcutaneously into the hind flank of wildtype C57BL/6 mice.  
Afterwards, tumors were monitored and measured weekly. A tumor size >15 mm 
in any direction was considered the endpoint, per IACUC regulations. Animals 
were then sacrificed and tissues were harvested for analysis. In separate 
experiments, LLC cells (1E6) that had been grown in control DMEM or FCM for 24 
hours were then injected into the hindflank in control DMEM or FCM and followed 
as described above.  
 
3.2.12 Tissue Processing and Histological Analysis  
Animals were sacrificed by CO2 administration in a closed chamber. Lungs 
were flushed with PBS, inflated at standard pressure with formalin, removed, and 
formalin-fixed for 48 hours. Lungs were then processed through increasing ethanol 
solutions in an STP 120 Spin Tissue Processor (ThermoFisher Scientific, 
Waltham, MA), paraffin-embedded, and sectioned (6 μm) using a JUNG RM2055 
microtome (Leica, Buffalo Groce, IL). Lung sections were then transferred onto 
charged, glass Colorfrost microslides (VWR Sciences, Radnor, PA) for histological 
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analysis. Sections were deparaffinized, rehydrated, and stained with hematoxylin 
and eosin (HE) to evaluate lung tumors.  
 
3.2.13 FCM Characterization via Antibody Array 
 A RayBio label-based (L-series) mouse antibody array L-308 membrane kit 
(# AAM-BLM-1-4) was used for FCM characterization, per the manufacturer’s 
instructions. Briefly, samples were dialyzed by loading 3 mL control DMEM and 
3mL FCM each into 2 dialysis vials, and then placed in 4 L PBS overnight at 4ºC. 
Samples were then transferred to 5 mL Eppendorf tubes and spun at 10,000 RPM 
for 5 minutes and transferred to new Eppendorf tubes. Labeling reagent was added 
and samples were incubated at room temperature for 30 minutes with gentle 
shaking. Stop solution was then added and samples were spun at 1000 x g for 3 
minutes using the provided spin columns. Membranes were blocked in provided 
blocking buffer for 1 hour at room temperature with gentle shaking. Samples were 
diluted 1:2 by mixing 5 mL sample with 5 mL blocking buffer. Membranes were 
then incubated at room temperature for 2 hours with gentle shaking. Membranes 
were washed three times per ten minutes with wash buffer #1 and three times per 
ten minutes with wash buffer #2. 500x HRP-conjugated streptavidin was diluted 
with 10 mL blocking buffer and membranes were incubated for 2 hours at room 
temperature. Membranes were then washed and exposed to detection buffer for 2 
minutes with gentle shaking. Membranes were placed between provided plastic 
sheets and imaged using Biorad’s ChemiDoc™ XRS+ System.  
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3.2.14 Analysis of Data 
 Means plus standard deviations of the mean were calculated for all 
experimental values, unless otherwise noted. Significance was assessed by using 
the Student's t test, unless otherwise noted. All experiments were repeated a 




3.3.1 FCM alters morphology of lung cancer cells 
Lung cancer cells were cultured in complete DMEM versus fibroblast-
conditioned media (FCM) for 5 days. FCM was obtained from IMR90 and WI38 
human lung fibroblasts when testing human cancer cells, and from primary murine 
lung fibroblasts when testing LLC cells. Afterwards, cells were formalin fixed, 
permeabilized, and stained with phalloidin and DAPI. FCM altered the morphology 
of A549, H1792, and LLC cells, but not H460 cells (Fig. 10A-D). This change in 
morphology was characterized by a spindle shape appearance, and was 
accompanied by cell scattering, both of which suggested the possibility of 
epithelial-mesenchymal transition (EMT), a marker of increased metastatic 
potential. To test this, cells were serum starved for 24 hours and then cultured in 
complete DMEM or FCM for 48 hours. Protein was then isolated, followed by  
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Figure 10. FCM Alters Lung Cancer Cell Morphology 
A549, H1792, H460, and LLC cells were grown in 96-well plates in control DMEM 
or FCM for 5 days, formalin fixed, permeabilized and stained with phalloidin and 
DAPI. FCM altered the morphology of all cell lines, with the exception of H460 
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Western Blot analysis for vimentin, E-cadherin, alpha smooth-muscle actin, and 
fibronectin. Very small changes were noted in all cell lines, except for H1792 cells, 
were alpha smooth-muscle actin, vimentin, and fibronectin levels were all 




















Figure 11. Effect of FCM on EMT Markers  
A549, H1792, H460, and LLC cells were grown in 6-well plates in control DMEM 
or FCM for 24 hours, serum starved for 24 hours, and then grown in FCM for an 
additional 48 hours. Protein was isolated, followed by Western Blot analysis (20 
µg) for fibronectin (FN, 1:1000), E-cadherin (Ecad, 1:500), Vimentin (Vim, 1:500), 
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3.3.2 FCM has differential effects on proliferation, migration, and colony 
formation 
 To examine the effects of FCM on lung cancer cell proliferation, cells were 
cultured in complete DMEM or FCM for up to 7 days.  All cell lines cultured in FCM 
showed increased proliferation, as determined by ATP quantification, when 
compared to cells grown in complete DMEM (Fig. 12A-D). Likewise, Transwell 
migration was increased in all cell lines (Fig. 13A-D), as determined by Boyden 
chamber migration assays, with the greatest effect being observed in H1792 cells. 
Additionally, colony formation of A549 cells was increased by the presence of FCM 
(Fig. 14A) but was unchanged in H1792 and H460 cells (Fig. 14B-C), while a 
decrease was observed in LLC cells (Fig. 14D). Lastly, wound healing, as 
determined by the scratch assay, was increased in A549, H1792 and LLC cells 
cultured in the presence of FCM, again, with the greatest effect being observed in 
H1792 cells. (Fig. 15A, B and D). Interestingly, FCM had no effect on wound 













Figure 12. FCM Increases Lung Cancer Cell Proliferation  
A549, H1792, H460, and LLC cells were grown in 48-well plates in control DMEM 
or FCM for 7 days. Cells were refed every 2-3 days. Cell proliferation was 
quantified using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega). 
Graphs depict relative luciferase units (RLU). Cell proliferation was increased in all 
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Figure 13. FCM Increases Transwell Migration  
A549, H1792, H460, and LLC cells (50,000) were plated in a Transwell Boyden 
inserts in serum- free media (200 µL) with control DMEM, IMR90 FCM, or WI38 
FCM in the lower well (700 µL). After 20-24 hours, cells were fixed and stained 
using the Kwik-Diff kit (Thermo Scientific). Inserts were then rinsed in dH2O and 
non-adherent cells on the inside of the insert were removed with a cotton swab 
and photographed. Transwell migration was increased in all cell lines tested in 
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Figure 14. Effect of FCM on Colony Formation  
A549, H1792, H460, and LLC cells plated in 24-well plates were suspended in 
0.4% top agar layer and plated on a 0.8% base agar layer, which was prepared 
according to Millipore’s instructions. Control DMEM or FCM was then added. 
Media was replaced every 3-4 days. Colonies were followed for 14 days and then 
counted and quantified using ImageJ software. Colony formation was increased in 
A549 cells and decreased in LLC cells in response to FCM, while no changes were 
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Figure 15. Effect of FCM on Wound Healing  
A549, H1792, H460, and LLC cells were plated in 6-well plates and allowed to 
grow overnight. A scratch was then created using a 1 mL pipette tip. Media was 
replaced with 5 mL control DMEM or FCM (10 mL for LLC cells). Photographs 
taken at 0 and 48 hours. Quantification was performed using ImageJ software. 
Wound healing was increased in all cell lines tested in response to FCM, except in 





3.3.3 FCM protects against cisplatin-induced death 
To evaluate the role of FCM in cisplatin-induced death, lung cancer cells 
were cultured in control DMEM or FCM for 24 hours. Cells were then exposed to 
cisplatin for an additional 28 hours. There was a significantly greater number of 
viable cells, after cisplatin exposure, when the cells were cultured in FCM 
compared to complete DMEM (Fig. 16A-D).  FCM-induced cisplatin protection was 
accompanied by a decrease in the activity of caspases 3 and 7 in all cells (Fig. 
17A,B and D), while no changes were observed in H460 cells (Fig. 17C). A 







Table 1. Effect of FCM  A549 H1792 H460 LLC 
Morphology Altered Altered No Change Altered 
Proliferation Increased Increased Increased Increased 
Transwell Migration Increased Increased Increased Increased 
Colony Formation Increased No Change No Change Decreased 
Scratch Migration Increased Increased No Change Increased 




Figure 16. FCM Decreases Sensitivity of Lung Cancer Cells to Cisplatin  
A549, H1792, H460, and LLC cells were plated in white-walled, clear-bottom 96-
well plates in control DMEM or FCM and allowed to grow overnight. Cisplatin 
(30µM, 100 µM, 30µM, and 10 µM, respectively) was then added and cells were 
allowed to grow an additional 24 hours. The remaining viable cells were quantified 
using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega). Graphs depict 
% of control cells that did not receive cisplatin. Units are relative luciferase units 
(RLU). All cell lines tested showed a decreased sensitivity to cisplatin in response 
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Figure 17. Effect of FCM on Caspase 3/7 Activation  
A549, H1792, H460, and LLC cells were plated in white-walled, clear-bottom 96-
well plates in control DMEM or FCM and allowed to grow overnight. Cisplatin 
(30µM, 100 µM, 30µM, and 10 µM, respectively) was then added and cells were 
allowed to grow an additional 24 hours. Caspase 3/7 activity was then detected 
using the Caspase-Glo 3/7 Assay Kit (Promega). Graphs depict % of control cells 
that did not receive cisplatin. Units are relative luciferase units (RLU). Caspase 3/7 
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3.3.4 Fibroblasts co-injected with LLC cells promote tumor growth, while 
FCM has small affect 
 Having established the effects of FCM on lung cancer cells in vitro, we 
focused our attention on the role of fibroblasts in vivo. First, primary lung fibroblasts 
and LLC cells were grown separately until cells were in exponential growth phase. 
Cells were then co-injected into the hindflank of C57BL/6 mice. Tumor growth was 
followed until tumors reached a size of 15 mm in any direction, after which time, all 
animals were sacrificed and lungs were harvested and formalin fixed. Primary lung 
fibroblasts and LLC cells injected together caused larger tumor growth at the site 
of injection at 18 days (sacrifice), compared to LLC cells alone (Fig. 18A). Primary 
lung fibroblasts injected alone did not cause tumors at the site of injection (data 
not shown). To evaluate lung metastasis, lungs were processed, paraffin 
embedded, sectioned, and H&E stained. As depicted in Fig. 18B, there were no 
differences in lung metastasis observed.  
 To evaluate the role that FCM plays in lung cancer metastasis, we grew 
LLC cells in FCM for 24 hours and then injected them into the hindflank of C57BL/6 
mice in FCM or complete DMEM. Tumor growth was again followed until tumors 
reached a size of 15 mm in any direction, after which time, all animals were 
sacrificed and lungs were harvested and formalin fixed. Although the number of 
metastases in the FCM group was greater in number than those in the complete 
DMEM group (2.6 vs 4.5), this was not statistically significant (Fig. 18D). Tumor 




Figure 18. Effect of PLF and FCM on Tumor Growth and Lung Metastasis In 
Vivo  
(A,B) 1E6 LLC cells (LLC, n=6) or 1E6 LLC cells with 1E6 PLF cells (LLC+PLF, 
n=7) were injected subcutaneously into the hind flank of WT C57BL/6 mice. (C,D) 
LLC cells were grown in control DMEM or FCM for 24 hours and then injected 
subcutaneously into the hind flank of WT C57BL/6 mice. A tumor size of ≥15mm 
in length or width was established as the endpoint according to IACUC regulations. 
Mice were then sacrificed and lungs harvested and processed for examination of 
metastases. Tumor volume was greater in the LLC+PLF group compared to LLC 
cells alone (A), while no differences in the number of lung metastases were 
observed (B). Tumor volume (C) and lung metastasis (D) was similar in animals 
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3.3.5 FCM Characterization 
 In order to identify the soluble component(s) present in FCM responsible for 
the observed effects, we began by utilizing Corning® Spin-X® UF Concentrators to 
determine the relative size of the ‘active’ agent.  Using columns with a molecular 
weight cutoff of 100 kDa, we were able to block the effects of FCM, with the 
exception of the protection from cisplatin-induced apoptosis, which indicates that 
most of the effects of FCM are due to factors greater than 100 kDa in size (not 
shown).  Other studies suggested that the activity was not mediated by molecules 
capable of interacting with RGD-binding integrins, as RGD peptides (used at 500 
ug/ml) did not block the effect. Heparin, boiling (100 ºC, 10 minutes), and proteases 
(PMSF), also failed to inhibit the activity suggesting that the soluble factor(s) in 
FCM is either not a protein, or a protein in a multiprotein complex, which protected 
it from degradation.  Lastly, several antagonists for fibroblast growth factor 
receptors (SU 6668, PD161570, and FIIN1 HCl), a well characterized mitogen of 
fibroblasts, also failed to inhibit the activity of FCM on proliferation (not shown).  
For a more targeted approach, we used RayBio AAM- BLM-1 label-based 
mouse antibody array, which simultaneously measures the expression of 308 
soluble murine proteins. Fifteen different proteins were identified in FCM that were 
not present in complete DMEM (Fig. 19). One of these proteins is hepatocyte 
growth factor (HGF) and is 105 kDa in size that is cleaved by serine proteases into 
a 69-kDa alpha-chain and 34-kDa beta-chain.  To determine if HGF was 
responsible for the observed effects of FCM on lung cancer cells, we tested the 
effects of a commercially available hepatocyte growth factor receptor (cMet) 
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Figure 19. FCM Characterization 
A RayBio label-based (L-series) mouse antibody array L-308 membrane kit (# 
AAM-BLM-1-4) was used for FCM characterization. Control DMEM or FCM 
samples were dialyzed and biotin labeled and then incubated with membranes 
containing 308 soluble mouse protein antibodies. Membranes were then washed 
and exposed to HRP-conjugated streptavidin, followed by ECL and then imaged 
using Biorad’s ChemiDoc™ XRS+ System. Red boxes indicate proteins present in 




























antagonist, PF 04217903 mesylate. The presence of PF 04217903 prevented the 
change in tumor cell morphology induced by FCM, except for in LLC cells, and 
blocked many, albeit, not all, of the effects of FCM (Table 2).  However, in all cell 
lines, it was unable to block the mitogenic effect of FCM, as well as the protective 
effect of FCM on cisplatin-induced apoptosis. 
 
To further investigate the identity of the component in FCM responsible for 
the effects on proliferation and cisplatin resistance, we charcoal stripped the FCM. 
Interestingly, the effects of FCM on cisplatin resistance were abolished with 
charcoal-stripped FCM (Fig. 20A-C). These data suggest that the components in 
FCM responsible for increasing resistance to cisplatin are non-polar materials such 
as lipids.  
 
 
Table 2. Effect of 
FCM + cMET 
Antagonist 
A549 H1792 H460 LLC 
Morphology Blocked Blocked No Change No Change 
Proliferation No Change No Change No Change No Change 
Transwell 
Migration 
Blocked Blocked No Change No Change 
Colony Formation No Change No Change No Change Blocked 
Scratch Migration Blocked Blocked No Change No Change 
Apoptosis 
Resistance 




Figure 20. Charcoal-Stripped FCM Blocks Protection Against Cisplatin. 
A549, H1792, H460, and LLC cells were plated in white-walled, clear-
bottom 96-well plates in control DMEM or FCM and allowed to grow overnight. 
Cisplatin (30µM, 100 µM, 30µM, and 10 µM, respectively) was then added and 
cells were allowed to grow an additional 24 hours. The remaining viable cells were 
quantified using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega). All 
cells lines tested showed a decreased sensitivity to cisplatin in response to FCM, 
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3.4 Discussion 
The prevailing paradigm of cancer for decades has been that a cell acquires 
mutations over its lifespan that eventually lead to a malignant phenotype and the 
development of cancer. However, this paradigm does not tell the entire story, and 
we now know that stromal cells in the tumor microenvironment are not idle 
bystanders, but co-evolve with transformed cells and play a crucial role in cancer 
progression. To date, the vast majority of research in this area has focused on the 
role of tumor or carcinoma-associated fibroblasts [143–145], and thus it has 
focused on what occurs after the tumor has already developed. Fewer studies 
have examined the role of normal lung fibroblasts, and thus what precedes tumor 
development. We hypothesized that normal, unstimulated fibroblasts of the lung 
also represent an important component of the tumor microenvironment that helps 
drive tumor progression, and that old fibroblasts would have an even greater effect 
on lung cancer cells. Consistent with this hypothesis, our studies show that normal 
lung fibroblasts produce a soluble substance(s) capable of altering cancer cell 
morphology and stimulating proliferation, migration, and colony formation of 
several NSCLC lines, as well as protecting against cisplatin-induced apoptosis in 
vitro.  We also observed an enhancement of primary tumor growth in vivo. With 
the exception of increased Transwell migration (not shown) however, FCM from 
old fibroblasts, did not show any differences compared to FCM from young 
fibroblasts (Table 3).  
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 Our observation that FCM promoted cell scattering and spreading, and a 
spindle-shape phenotype in three of four cell types suggested the breakdown of 
intercellular junctions and epithelial-mesenchymal transition (EMT). However,  
 
except for increased vimentin, fibronectin and alpha smooth muscle actin levels in 
H1792 cells, little to no changes were observed in A549, H460 and LLC cells. 
These data suggest that EMT, as it is classically defined, was not responsible for 
the observed changes in morphology. Interestingly, at least one group has shown 
that the behavioral and morphological changes that accompany EMT are not 
necessarily linked. For example, cadherin switching is necessary for increased 
motility, but not the morphological changes that accompany EMT [146].  
FCM affected several other processes and, as presented in Table 1, we 
observed differential effects of FCM on A549, H1792, H460 and LLC cells in 
several functional assays.  For example, FCM stimulated Transwell migration in all 
cell lines tested, but this effect was much greater in H1792 cells. FCM increased 
migration across a wound in all cell lines, except H460 cells. Interestingly, colony 
formation was increased in A549 cells in response to FCM, but was unchanged in 
H1792 and H460 cells, and a decrease was observed in LLC cells. Lastly, FCM 
could protect all cell lines from cisplatin-induced death. This was accompanied by 
Table 3. Effect of FCM from Old vs. Young PLF 
on: 
LLC 
Morphology No Change 
Proliferation No Change 
Transwell Migration Increased 
Colony Formation No Change 
Scratch Migration No Change 
Apoptosis Resistance No Change 
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a decrease in the activity of caspases 3 and 7 in A549, H1792 and LLC cells, but 
not in H460 cells. There is precedent for human lung cancer cell lines behaving 
differently when studied in the laboratory. For example, Liang et al, demonstrated 
a decrease in cell proliferation in A549 cells, compared to a stimulation of cell 
proliferation in SK-MES-1 cells, when exposed to Budesonide, a PPARa and 
glucocorticoid receptor agonist. This differential effect was attributed to a mutation 
in TP53 in SK-MES-1 cells [147]. Additionally, Ling et al, showed that 
overexpression of MTSS1 enhanced the invasion and proliferation abilities of H920 
and H1581 cells, while it inhibited invasion and proliferation in SW900 cells. These 
differential effects were shown to be due to differences in FAK phosphorylation and 
activity [148]. Our observations that FCM displayed differential effects depending 
on what cell line was used, could explain differences observed in the literature 
when comparing normal fibroblasts to carcinoma-associated fibroblasts. According 
to the Cancer Cell Line Encyclopedia (CCLE) [149,150], a collaboration between 
the Broad Institute, and the Novartis Institutes for Biomedical Research and its 
Genomics Institute of the Novartis Research Foundation, the A549, H1792, and 
H460 cell lines used in these studies have hundreds of mutations (785, 396, and 
514, respectively). A search of the CCLE for common mutations known to NSCLC 
revealed interesting findings. The KRAS gene was the only gene mutated in all 3 
cell lines. A mutation in the p53 gene was only observed in H1792 cells. STK11 
was mutated in A549 and H460 cells, while STK10 was mutated in H1792 cells. 
CDKN2A is also mutated in A549 cells and H460 cells, but not H1792 cells. Lastly, 
there are no known mutations in the EGFR or ALK genes. The differential effects 
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in response to FCM could indeed be due to these differences in the genetic profile 
of the cell lines used. Further research is needed in this area.  
The observation that FCM protected both human cell lines and LLC cells 
from cisplatin-induced apoptosis through effects on caspase activity is quite 
intriguing as it suggests that host fibroblast-derived soluble factors, and not only 
physical interaction, may influence the impact of chemotherapy on tumors.  
Cisplatin is a recognized cornerstone in the treatment of lung cancer. 
Unfortunately, some tumors are unresponsive, or more quickly become resistant. 
To date, there are no agents in the clinic that circumvent this problem. Cisplatin 
acts largely by promoting the formation of DNA adducts, mainly intrastrand 
crosslinks, as well as inducing oxidative stress [151,152].  This triggers TP53 and 
MAPK signaling, among others, resulting in the induction of apoptosis.  Thus, one 
must assume that the protective effects of FCM are due to inhibition of drug activity, 
drug uptake, or over expression of anti-apoptotic signals (e.g., bcl-2). Interestingly, 
our observations that FCM protected lung cancer cells from cisplatin-induced 
death is not in agreement with Bartling et al, who showed that conditioned media 
from WI38 fibroblasts could protect H358 cells from apoptosis induced by 
paclitaxel, but not by cisplatin. [153]  Our data indicate that one possible approach 
to circumventing cisplatin resistance in the clinic would be to simultaneously target 
fibroblast signaling in the tumor stroma during chemotherapy. At least one group 
has shown that cisplatin resistance could be abrogated by inhibiting mTOR 
signaling [154]. 
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Of all the effects of FCM, stimulation of proliferation was the most consistent 
in all cell lines, and interestingly, this effect was not diminished by blocking cMET 
(Table 2). This is intriguing because aberrant HGF/cMET signaling has been 
shown to promote an oncogenic phenotype in various tumor types, including lung 
cancers [155]. Moreover, boiling the media, blocking FGFR, and blocking the PI3K 
and ERK pathways also had no effect (not shown). While this proliferative effect of 
FCM was not observed in vivo, co-injection of fibroblasts and tumor cells together 
increased primary tumor growth. This is likely due to the fact that the effects of 
FCM are lost quickly in vivo, while fibroblasts co-injected with LLC cells persist and 
thus their effects are long lasting.  
The activity of FCM was impressive in certain assays, but was limited in its 
influence in vivo in our models. Nevertheless, identifying the agent(s) present in 
FCM responsible for these effects might unveil potential targets for intervention 
that could be used in the clinic. We found that FCM was characterized by altering 
cancer cell morphology and stimulating proliferation, migration, and colony 
formation of several NSCLC lines, as well as protecting against cisplatin-induced 
apoptosis in vitro.  We also observed an enhancement of primary tumor growth in 
vivo, in immunocompetent animals. Many of these effects, but importantly, not all, 
were due to HGF.  
Altogether, these observations suggest that FCM contains not one but 
several factors capable of influencing tumor cell behavior. Our data showing 
differential effects of FCM, depending on the cell type, also indicate that the role 
that fibroblasts play in lung cancer progression is not as simple as a one approach 
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fixes all, but is rather complex. Thus, our data suggest that targeting the tumor 
stroma alone, or in combination with chemotherapy, is a promising concept that 




THE ROLE OF REDOX AND SEX IN LUNG CANCER 
 
4.1 Introduction 
 Oxidative stress, classically defined as an imbalance between antioxidants 
and pro-oxidants, has been implicated in a number of physiological and clinical 
disorders ranging from aging and cardiovascular disease to pulmonary diseases, 
diabetes, and cancer [156–159]. However, unfortunately, large-scale 
interventional studies designed to shift the balance of antioxidants and pro-
oxidants in favor of the former have failed to show significant benefits in health 
outcomes of several diseases [80–83]. As mentioned in the introduction to this 
dissertation, it was suggested that the reason for the failure of these antioxidant 
trials has been a misunderstanding of what oxidative stress actually is. Thus, 
attention towards newer and better antioxidants may not yield better results until a 
new definition of oxidative stress is considered, and treatment accordingly. Dean 
Jones at Emory University has proposed a new definition as “a disruption of redox 
signaling and control” [84], and has developed a way of quantifying oxidative stress 
as the measurement in plasma of the redox potential (Eh) for the thiol disulfide 
couples cysteine (Cys) and its oxidized form cystine (CySS), termed Eh Cys/CySS. 
This is minimally invasive and represents a measure of global redox state. Eh 
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Cys/CySS has been measured in humans as well as in rats, but knowledge about 
the factors that influence Eh Cys/CySS in murine models is very limited, and 
studies in this area have used different animal models and diverse measures of 
oxidative stress. Taken together, these justify the use of animal models to test the 
impact of oxidant stress and various interventions on disease development.  To 
gain insight into this area, we examined the effects of age, sex, fasting, and diets 
on the plasma Eh Cys/CySS of C57BL6 mice and what role alterations in the Eh 
Cys/CySS have in lung cancer progression in the LLC model of lung cancer. These 
studies should redirect our efforts to identify key alterations in redox signaling in 
oxidative stress-related diseases that will then hopefully lead to new targets for 
treatment. 
 
4.2 Materials and Methods 
4.2.1 Reagents 
 All reagents were purchased from Sigma Chemicals (St. Louis, MO) or 
Fisher Scientific (Pittsburgh, PA) unless otherwise noted.  
 
4.2.2 Cell Culture  
 Lewis Lung Carcinoma (LLC; CRL-1642) cells were purchased from ATCC 
(Rockville, MD) and grown in DMEM supplemented with 10% FBS, at 37 ºC in a 
humidified 5% CO2 incubator. The percentage of CO2 was periodically checked 
and recalibrated to maintain 5%. Cells were used within 3 months of resuscitation.  
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4.2.3 Plasma Redox Potential Measurements 
 Blood was isolated retro-orbitally under isoflurane anesthesia, using 
heparinized micro-hematocrit capillary tubes and immediately transferred to a 1.5 
mL centrifuge tube containing 20 µL of L-serine, heparin, bathophenanthroline 
disulfonic acid, sodium iodoacetate, and γ-glutamyl glutamate (internal standard), 
and spun at 16,000 ×g for 1 minute. 100 µL of supernatant were transferred to a 
new centrifuge tube containing 100 µL boric acid and perchloric acid. Samples 
were mixed and frozen at -80 ºC until further use (typically 24 hours). For analysis, 
samples were thawed centrifuged at 16,000 ×g for 1 minute to remove precipitated 
proteins. 150 µL of supernatant were then added to 30 µL of iodoacetic acid in a 
new 1.5 mL Eppendorf tube and vortexed. The pH was then adjusted to 9.0 +/- 0.2 
using 1M KOH in KBO4. Afterwards, samples were incubated at room temperature 
for 20 minutes after which time, 150 µL dansyl chloride was added and samples 
vortexed and incubated 24 hours at room temperature in the dark. Lastly, 250 µL 
CHCI3 were added and samples vortexed and analyzed by HPLC (Waters 
Corporation, Millford, MA) to determine molar concentrations of cysteine, cystine, 
glutathione, and glutathione disulfide, which were then used in the Nernst equation 
to determine the plasma redox potential. 
 
4.2.4 Animal Studies 
All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Louisville.  LLC cells were plated out 24 hours prior 
to injections and were harvested at ~50% confluence to ensure cells were in 
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growth phase.  LLC cells (1E6 /100 μl sterile PBS) were injected subcutaneously 
into the hind flank of wildtype C57BL/6 mice under isoflurane anesthesia.  
Afterwards, tumors were monitored and measured weekly. A tumor size >15 mm 
in any direction was considered the endpoint, per IACUC regulations. Animals 
were then sacrificed and tissues were harvested for analysis.  
 
4.2.5 Sulfur Amino Acid Diets 
 Diets were custom-prepared by Harlan-Teklad and were designed to be 
isonitrogenous. The study was designed to evaluate the response of female mice 
to a diet deficient in sulfur amino acids (SAA deficient) or to a diet with excess SAA 
(SAA excess). The effect of these was compared to those of an SAA control diet. 
The deficient diet contained no cystine, and a reduced amount of methionine, while 
the excess diet contained 3x the amount of cystine and 1.8x the amount 
methionine compared to the SAA control diet.  A fourth group of mice was fed a 
standard chow diet. Female mice, aged 3 months old were randomly divided into 
4 groups (n=10 each), and were given the following diets for 6 months: chow, SAA 
control, SAA deficient, SAA excess.  
 
4.2.6 Tissue Processing and Histological Analysis  
Animals were sacrificed by CO2 administration in a closed chamber. Lungs 
were flushed with PBS, inflated at standard pressure with formalin, removed, and 
formalin-fixed for 48 hours. Lungs were then processed through increasing ethanol 
solutions in an STP 120 Spin Tissue Processor (ThermoFisher Scientific, 
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Waltham, MA), paraffin-embedded, and sectioned (6 μm) using a JUNG RM2055 
microtome (Leica, Buffalo Groce, IL). Lung sections were then transferred onto 
charged, glass Colorfrost microslides (VWR Sciences, Radnor, PA) for histological 
analysis. Sections were deparaffinized, rehydrated, and stained with hematoxylin 
and eosin (HE) to evaluate lung tumors.  
 
4.3 Results 
4.3.1 Plasma Eh Cys/CySS is Unchanged in Aged Mice but Females are 
More Oxidized Compared to Males 
 Previous publications have demonstrated an oxidation of the plasma Eh 
Cys/CySS and Eh GSH/GSSG in aged humans [78]. To determine if this occurs in 
mice, plasma from young (3 months) and old (24 months) male and female mice 
was isolated and analyzed by HPLC for molar concentrations of Cys, CySS, GSH, 
and GSSG. We observed that aging did not impact the Eh Cys/CySS or the Eh 
GSH/GSSG in male or female mice tested at 3 vs. 24 months of age (Fig. 21A-
B). However, interestingly, females were more oxidized when compared to males 
(Fig. 22). This was mainly due to differences in Cys concentration but not to total 
Cys intake. The levels of glutathione (GSH) and glutathione disulfide (GSSG) were 






Figure 21. Plasma Eh Cys/CySS and Eh GSH/GSSG are Unchanged in Old 
Mice  
Blood was isolated retro-orbitally from young (3 months) and old (24 months) 
male and female WT C57BL/6 mice (n=8 in each group) under anesthesia, using 
heparinized micro-hematocrit capillary tubes and immediately prepared for 
analysis by HPLC. Plasma Eh Cys/CySS values were: young female = -91.7 +/- 
4.9 mV; old female = -95.4 +/- 7.4 mV; young male = -108.6 +/- 9.4 mV; old male 
= -104.3 +/- 3.9 mV. Plasma Eh GSH/GSSG values were: young female = -156.7 
+/- 6.6 mV; old female = -152.7 +/- 4.8 mV; young male = 166.4 +/- 7.4 mV; old 
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Figure 22. Female Plasma Eh Cys/CySS is More Oxidized Compared to Males  
Blood was isolated retro-orbitally from male (n=10) and female (n=9) WT C57BL/6 
mice (3 months), under anesthesia, using heparinized micro-hematocrit capillary 
tubes and processed as described in Figure 1. Plasma Eh Cys/CySS values were: 
male = -108.6 +/- 5.0 mV; female = -95.2 +/- 5.7 mV; Cys values were: male = 34.3 


























4.3.2 Female Mice are More Susceptible to LLC Lung Cancer Metastasis 
 Since female mice were found to be more oxidized in their Eh Cys/CySS, 
and data in the literature suggests females are at an increased risk of lung cancer, 
we speculated they may be more susceptible to lung cancer metastasis in the LLC 
model. A retrospective analysis of LLC lung cancer studies in our laboratory 
indicated that female mice may indeed be more susceptible to lung cancer 
metastasis compared to males (data not shown). To test this prospectively, adult 
(11-12 months) male and female mice were injected subcutaneously with LLC cells 
and followed for tumor development. Paradoxically, tumor volume at the site of 
injection was smaller for female mice (Fig. 23B), while metastasis to the lung was 

















Figure 23. Female Mice are More Susceptible to LLC Lung Cancer Metastasis  
1E6 LLC cells were injected subcutaneously into the hindflank of WT male (11 
months, n=6) and female (12 months, n=10) C57BL/6 mice. Per IACUC regulations 
of endpoints, tumor formation and size were followed until a tumor size of ≥15mm 
in length or width was established. All mice were then sacrificed (day 18) and lungs 
harvested and processed for examination of metastases. Female mice developed 









































4.3.3 Sulfur Amino Acid Diets and Fasting Affect Plasma Eh Cys/CySS 
 The observation that female mice had a more oxidized Eh Cys/CySS 
compared to males and were more susceptible to lung cancer metastasis in the 
LLC model, led us to examine whether the two were related. To test this, we first 
needed to determine if we could manipulate the Eh Cys/CySS in female mice. 
Thus, female mice were placed on diets with different concentrations of sulfur 
amino acids, designed to oxidize or reduce their plasm Eh Cys/CySS. Mice were 
placed on the diets at 3 months of age. After 6 months, plasma was harvested and 
processed for HPLC analysis. A diet containing excess sulfur amino acids was 
able to significantly reduce the plasma Eh Cys/CySS (-93.6 +/- 10.0 vs.-103.4 +/9.0 
mV, P = .03), while a diet deficient in sulfur amino acids was unable to significantly 
oxidize the mice when compared to the SAA control diet (-93.6 +/- 10.0 vs.-86.3 
+/6.8 mV, P = .07) (Fig. 24). There have been reports in the literature of a diurnal 
pattern of variation of plasma redox potential that correlated with meal intake [160]. 
To determine if this occurred in mice, blood was drawn from young male and 
female mice before and after a 24 hour fast. Interestingly, fasting did not affect Eh 
Cys/CySS in females, but resulted in oxidation of the males to levels similar to 
those of females (Eh Cys/CySS -96.2 mV vs. -98.8 mV) (Fig 25A). This oxidation 
was caused by a decrease in the plasma levels of Cys due to fasting (34.3 +/- 5.9 







Figure 24. Diets Containing Excess Sulfur Amino Acids Reduce the Plasma 
Eh Cys/CySS  
Female WT C57BL/6 mice (3 months; n=10 in each group) were fed a standard 
chow diet, or diets with differing amounts of sulfur amino acids for 6 months. Blood 
was then isolated and processed as described in the methods section. (A) Plasma 
Eh Cys/CySS values were: chow = -91.7 +/- 3.0 mV; SAA control = -93.6 +/- 10.0 
mV; SAA deficient = -86.3 +/- 6.8 mV; SAA excess = -103.4 +/- 9.0 mV; (B) Cys 
values were: chow = 19.3 +/- 2.4 µM; SAA control = 20.3 +/- 6.2 µM; SAA deficient 
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Figure 25. Fasting Alters Plasma Eh Cys/CySS in Male Mice but Not Female 
Mice 
Blood was isolated retro-orbitally from male (n=10) and female (n=9) WT C57BL/6 
mice (3 months), under anesthesia, using heparinized micro-hematocrit capillary 
tubes and processed as described in Figure 1. Mice were allowed to recover for 
one week and were then fasted for 24 hours. Blood was again drawn and 
processed in the same manner. (A) Unfasted plasma Eh Cys/CySS values were: 
male = -108.6 +/- 5.0 mV; female = -95.2 +/- 5.7 mV. Fasted values were: male = 
-98.8 +/- 3.8 mV; female = -96.2 +/- 5.0 mV. (B) Unfasted Cys values were: male 
= 34.3 +/- 5.9 µM; female = 21.5 +/- 3.8 µM. Fasted Cys values were: male = 23.2 
+/- 2.7 µM; female = 21.8 +/- 5.9 µM. * = significant difference between unfasted 












4.3.4 Alterations in Plasma Eh Cys/CySS Have No Effect on LLC Lung Cancer 
Progression 
 Having characterized the effects of the SAA diets in mice, we set out to 
determine if oxidation of the plasma Eh Cys/CySS in female mice was the cause 
of their increased susceptibility to lung cancer metastasis. To test this, we injected 
LLC cells into adult female mice on the aforementioned SAA diets. As depicted in 
Fig. 26, oxidation of the Eh Cys/CySS had no effect on the percentage of animals 




















Figure 26. Alterations in Plasma Eh Cys/CySS Have No Effect on LLC Lung 
Cancer Progression  
Mice on SAA diets (described in Figure 4) were injected 1E6 LLC cells at 9 months 
of age subcutaneously into the hindflank and followed for tumor size. Once tumors 
reached a size of 15mm in any direction, all mice sacrificed, and lungs harvested 
and processed for examination of metastases. No differences were observed in 
the percentage of mice in each group that developed tumors (A), nor were 
differences observed in the number of metastases in the lungs of animals in each 
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Oxidative stress occurs with aging and is associated with multiple age-
related diseases, such as type-2 diabetes and cardiovascular disease. Non-
invasive methods to quantify oxidative stress have been lacking until recently. 
Moreover, a misunderstanding of oxidative stress and treatment accordingly, has 
led to the dismal failure of clinical trials in several large-scale interventional studies. 
Cysteine and its disulfide form cystine, form the major low molecular weight 
thiol/disulfide pair in extracellular fluids. Emerging evidence has shown that the 
balance between cysteine and cystine, measured as their redox potential (Eh 
Cys/CySS), can be a marker of oxidative stress and thus an important health 
determinant. Dean Jones has shown that in young, healthy individuals, the Eh 
Cys/CySS is around -80 mV  [161] and that this value becomes more oxidized with 
age [78], smoking [162] and disease, such as cardiovascular disease [79]. Taken 
together, these data warrant the need for the development of murine models in 
order to study oxidative stress further, as well as means of intervention. We thus 
set out to study oxidative stress in a murine model, and what role this had in lung 
cancer progression in the LLC model. Several observations were made as 
summarized below. 
First, no changes were observed in either the Eh Cys/CySS or the Eh 
GSH/GSSG with regard to aging in male or female mice. This is interesting 
because the progressive oxidation of Eh Cys/CySS and the Eh GSH/GSSG in 
humans has been shown to occur with aging, at a pace of 0.7 mV per year after 
age 45 for the Eh GSH/GSSG, and 0.2 mV a year from age 18 onward for the Eh 
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Cys/CySS [78], [163]. Eh Cys/CySS values in our studies ranged from -91.7 +/- 
4.9 mV to -108.6 +/- 9.4 mV which is consistent with the range reported for mouse 
plasma [164], but more reduced compared to human plasma [78]. Likewise, values 
for the Eh GSH/GSSG ranged from -152.7 +/- 4.8 mV to 166.4 +/- 7.4 mV, again, 
slightly more reduced compared to human plasma. The difference of ~50 mV 
between these thiol/disulfide couples indicate that they are not in equilibrium, and 
thus the classical definition of oxidative stress as simply an imbalance between 
pro-oxidants and anti-oxidants, is simple unacceptable. These data are important 
and suggest that murine models may not be acceptable models to study the 
progressive oxidation of thiol-disulfide couples that occur with aging. Although we 
observed no effect with aging, we did observe that female mice were oxidized in 
their Eh Cys/CySS, but not in their Eh GSH/GSSG when compared to males, 
regardless of age. Studies in humans have showed no differences in regard to sex, 
but these studies were not designed specifically to examine the role of sex, and 
are therefore not conclusive. The reasons for these differences in female mice 
remain unexplained.  
Second, we observed that while female mice developed smaller tumors at 
the site of injection, they were more susceptible to lung cancer metastasis in the 
LLC subcutaneous model of lung cancer. It has been reported in humans that 
females typically have smaller tumors [165]. There are also numerous studies in 
the literature detailing an increased risk of lung cancer in humans in both smokers 
and particularly in never-smokers [99,166–170]. Several mechanisms have been 
proposed, but of particular interest is the role of estrogens, which have been 
	 98	
proposed to lead to increased amounts of oxidative DNA damage [171,172]. 
Smoking has been shown to increase the levels of CYP1B1, which is expressed 
in the lung. CYP1B1 then metabolizes estrone (E1) and 17b-estradiol (E2) into the 
catechol estrogens, 4-OHE1 and 4-OHE2, respectively. These catechol estrogens 
then lead to DNA damage [173,174].  It is important to note that others are not in 
agreement with the notion that females are more susceptible to lung cancer 
[175,176].  
Third, we showed that we were able to significantly reduce the Eh 
Cys/CySS in female mice using diets that were deficient in certain sulfur amino 
acids. We were, however, unable to significantly oxidize these same animals by 
using diets with excess amounts of sulfur amino acids. This has been evaluated in 
rats, where a diet deficient in SAA was shown to significantly oxidize the Eh 
Cys/CySS, and diet with excess SAA was able to significantly reduce the Eh 
Cys/CySS [177]. It has been shown that oxidative stress is reduced in those 
consuming a Mediterranean diet [178]. There is also evidence showing that tissue 
levels of GSH can be affected by dietary inducers [179]. Thus, there is a need to 
understand the dietary factors that affect Eh Cys/CySS and Eh GSH/GSSG.  The 
data presented here are important in that they allow for interventional studies in a 
murine model, which will possibly help shed light on what occurs in humans [180]. 
Lastly, the increased susceptibility of female mice to lung cancer metastasis 
does not appear to be due to the fact that they are more oxidized in their Eh 
Cys/CySS. The canonical view of oxidative stress in terms of cancer is that ROS 
contribute to malignant progression of tumors by promoting, among others, 
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genomic instability. Indeed, oxidative stress has been shown to promote cancer 
progression in several studies, evidenced by the use of antioxidants. For example, 
Gao et al., reported anti-tumorigenic effects of N-acetyl cysteine (NAC) and vitamin 
C in multiple tumorigenic murine models. It was shown that this effect was not only 
due to decreased levels of DNA damage, but also to decreased levels of HIF [181]. 
NAC was also shown to slow tumor progression in p53-dependent mouse model 
of lymphomagenesis [182]. However, paradoxically, others have shown that 
oxidative stress can inhibit cancer metastasis. Wu et al., showed that the ability of 
isothiocyanates to decrease the metastatic potential of NSCLC lines was due to 
their induction of oxidative stress [183]. Additionally, Piskounova et al., reported 
that anti-oxidants promoted distant metastasis of melanoma cells in NSG mice, 
while having no effect on the growth of the primary tumor [184]. These latter 
observations, among others, have posited some to describe metastasis as an 
escape from oxidative stress [185]. Our studies involving SAA diets were unique, 
in that they could test whether or not oxidative stress could inhibit or promote 
metastasis. If oxidation of the Eh Cys/CySS was important in LLC lung cancer 
progression, the biggest difference would be observed between SAA excess and 
SAA deficient diet groups. However, we observed no differences in lung cancer 
metastasis between these groups. It could be argued that one of the reasons we 
failed to see differences is due to a small mV change due to the diets (10-15mV). 
However, a 15 mV change in redox potential, will cause a 5-fold change in a dithiol/ 
disulfide motif [186].  Another explanation may be related to the short time frame 
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of the studies, which cannot possibly mimic the human conditions where exposure 
to pro-oncogenic factors may last years. 
Taken together, this work extends our understanding of redox changes with 
regard to aging and fasting, 2 major life processes. It was surprising that while a 
24 hour fast was able to significantly oxidize male mice, aging had no effect on 
redox state in either sex. Interestingly, this same phenomenon has been observed 
in Drosophila melanogaster [187]. These data suggest that redox processes are 




SUMMARY AND DISCUSSION 
 
5.1 Restatement of Goals 
 Lung cancer occurs almost exclusively in elderly individuals. In fact, only 3-
5% of lung cancers occur in individuals under the age of 40.  Aging is characterized 
by multiple abnormalities, such as increased oxidative stress, chronic 
inflammation, decreased immune function, and alterations in tissue ECM. Lung 
cancer also commonly occurs in those with pre-existing pulmonary diseases such 
as COPD and IPF (also increased in the elderly), which are marked by lung 
inflammation and tissue remodeling. Although the majority of lung cancers occur 
in former or active smokers, only 20% of lifetime smokers will acquire lung cancer. 
Moreover, data in the literature using old animals to study lung cancer are scarce, 
contradictory, and usually evaluated only primary tumor growth at the site of 
injection [188]. For this reason, we set out to explore what host factors in the elderly 
are responsible for the increased susceptibility to lung cancer, by testing the 
following hypothesis:  while smoking and other environmental exposures can lead 
to lung cancer development in a genetically susceptible individual, increased 
oxidation of the Eh Cys/CySS in the aging lung creates an oncogenic 
microenvironment, specifically by increased fibronectin EDA levels, that renders 
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the host susceptible to lung cancer progression (Figure 1). Several observations 
were made as summarized below. 
 
5.2 Main Findings of This Dissertation 
 Through both subcutaneous and intravenous injection of LLC cells, we 
showed that aged C57Bl/6 mice were more susceptible to lung cancer progression, 
marked by increased metastases to the lung in the subcutaneous model, and an 
increased number of tumors in the lung in the intravenous model. This effect of 
aging is in agreement with those of Gozez and Trainin who showed tumor 
incidence and growth rate of the primary tumor was increased in direct proportion 
to age in C57Bl/6 mice injected subcutaneously with LLC cells (metastasis was not 
evaluated) [189]. Yuhas and Ulrich also showed an increase in lung tumors with 
aging using Line 1 cells [190]. In contrast, Ershler found decreased survival and 
increased metastasis in younger animals using LLC cells and B16 melanoma cells 
[191]. Lastly, Anisimov and Zhukovskaya, using LLC cells, showed no effect of age 
on the growth of the primary tumor or survival (metastasis was not evaluated).  
[192]. These contradictory reports suggest differences in animal models and 
methodology, while emphasizing the need for further research in this area.  
Interestingly, one of the proposed causes of these discrepancies has been the sex 
of mice used, as many of the earlier studies did not indicate what sex was tested.  
In this dissertation, we have outlined that female mice are indeed more susceptible 
to lung cancer metastasis in the LLC model when compared to males, and develop 
larger tumors at the site of injection. Our data clearly showed that aging renders 
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the host susceptible to lung cancer progression in the LLC model. This ‘aging 
effect’ does not appear related to tumor implantation, growth, or metastasis from 
the primary tumor, and the effects of immunity appear limited.  Instead, the aging 
effect appears to be ‘lung dependent’. Our lab has previously shown that the aged 
murine lung is characterized by a pro-fibrotic phenotype. Considering this, we 
hypothesized that the aging effect related to the extracellular matrix deposited in 
the microenvironment.  To test this, we engaged in studies using fibronectin EDA 
KO mice. However, we showed that fibronectin EDA was not important for lung 
cancer progression in uninjured lungs.  
Fibronectin EDA is increased in the aged lung and has been shown to be a 
vascular marker for solid tumors and metastases. Moreover, immunization against 
fibronectin EDA decreases tumor burden and lung metastases in the MMTV-PyMT 
transgenic model of metastatic mammary carcinoma. This and other observations 
justify testing fibronectin EDA. Nevertheless, we observed no differences in 
primary tumor growth, or metastases to the lung in the LLC model when using 
fibronectin EDA KO mice. As mentioned in the Future Studies section, studies are 
ongoing using KRAS mice to determine if EDA has a role in lung cancer 
development.  
Third, by using the bleomycin model of pulmonary fibrosis, followed by 
injection of LLC cells, we showed that lung inflammation/tissue remodeling 
increased metastases to the lung, but only in aged mice, and not young mice. Due 
to reports that fibronectin EDA KO mice were protected from bleomycin-induced 
pulmonary fibrosis, we chose to use these animals to begin to determine the 
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mechanisms increased tissue remodeling in the lung played in LLC lung cancer 
progression. In our hands, fibronectin EDA KO mice were found to develop the 
same degree of pulmonary fibrosis as WT mice. We repeated these experiments 
several times in both male and female mice. Surprisingly, despite the presence of 
pulmonary fibrosis, bleomycin was unable to increase metastases to the lung in 
fibronectin EDA KO mice, suggesting that EDA plays a crucial role for lung cancer 
progression in the setting of aging and lung injury. In WT animals treated with 
bleomycin, we observed that ~90% of metastases to the lung occurred in areas of 
fibrosis. This was not observed in fibronectin EDA KO mice, which suggests that 
EDA acts a scaffold for the recruitment and organization of tumor cells in the lung.  
This is consistent with our observation that most metastatic lesions co-localized 
with areas of tissue remodeling.  Additionally, in vitro, we observed that fibronectin 
EDA increased proliferation and migration of LLC cells.  
Fourth, we found that immunity played an important role in age-related 
susceptibility to lung cancer progression in the LLC model. The differences in 
young vs. old WT mice were abolished in NSG mice. Young NSG mice developed 
metastases to the lung while young WT animals did not, suggesting that young WT 
animals are able to successfully mount a defense against lung cancer progression. 
While the number of metastases to the lung in aged NSG mice was still greater 
than those in young NSG mice, this was not statistically significant. However, 
importantly, the size of the lung tumors in the aged NSG mice were significantly 
larger than those observed in young NSG mice. These data support our hypothesis 
that the microenvironment of the aged lung (specifically alterations in ECM 
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proteins) itself renders the host susceptible to lung cancer progression. The cause 
of the differences in location of lung metastases in WT vs. NSG mice remain 
unexplained.  
Fifth, we observed no changes in the oxidation of either the Eh Cys/CySS 
or the Eh GSH/GSSG with aging in mice. Oxidation of these thiol/disulfide couples 
has been shown to occur in humans, and our lab has previously reported that 
oxidation of the Eh Cys/CySS in lung fibroblasts alters matrix gene expression, 
specifically, increased expression of fibronectin and the growth factor TGFb. For 
these reasons, we hypothesized that the increased susceptibility of old mice to 
lung cancer progression was due to oxidation of the Eh Cys/CySS, which led to 
altered matrix composition in the old lung. While this was not found to be the case, 
we observed that female mice were more oxidized in their Eh Cys/CySS, but not 
in their Eh GSH/GSSG, when compared to males. We also observed that female 
mice were more susceptible to lung metastases in the LLC model. To determine if 
these were related, we engaged in studies using SAA diets. We were able to 
significantly reduce the Eh Cys/CySS in females to levels observed in males. 
However, this had no effect on lung metastasis to lung, suggesting that oxidation 
of thiol/disulfide couples has no role in aging or lung cancer progression in mice. 
We suspect that the time frame of the experiments prevented us from observing a 
differential effect.  Our studies were performed within weeks of the intervention, 
while humans are likely oxidized for years prior to the latter promoting alterations 
in ECM composition and having a pro-oncogenic effect.  Either way, it remains to 
be determined why aged, female WT mice are more susceptible to lung cancer 
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progression in the LLC model. Interestingly, females were found to have increased 
levels of fibronectin EDA in whole lung homogenates (Fig. 27).  
Lastly, we showed that normal, untransformed lung fibroblasts play an 
important role in lung cancer progression. Fibroblasts are the predominant cell type 
in the tissue stroma and are the main source of ECM proteins. As such, they play 
prominent roles in tissue remodeling and thus pulmonary fibrosis. Our lab has also 
shown that old fibroblasts have defects in control of their redox state. This was 
found to be due to a 10-fold decreased expression of the Slc7a11 subunit of the 
xCT cystine-glutamate transporter in primary lung fibroblasts harvested from 24-
month old mice. For this reason, we engaged in studies evaluating the role that 
young and old fibroblasts played in lung cancer progression. Based on the vast 
number of reports in the literature studying cancer-associated fibroblasts (albeit 
few in the lung), we hypothesized that ‘normal’ young fibroblasts would play little 
to no role in lung cancer progression and that old fibroblasts would. Surprisingly, 
FCM from normal young fibroblasts was found to alter the morphology of several 
lung cancer cell lines, as well as increase their proliferation, confer resistance to 
cisplatin, increase colony formation, increase Transwell migration, and increase 
wound healing. Little differences were observed between the effect of FCM from 
young and old fibroblasts. Despite large differences observed in vitro in response 
to FCM, we observed no differences in vivo in metastases to the lung or growth of 
the primary tumor. We did, however, observe larger tumors at the site of injection 




Figure 27. FNA EDA Protein Levels in Female and Male Whole Lung 
Homogenates 
Protein was isolated from female (n=4) and male (n=4) murine whole lung 
homogenates followed by Western Blot analysis for FN EDA (Abcam, ab6328; 
1:400) and GAPDH (Sigma, G9545; 1:10,000). Blots were scanned on a LI-COR 
Odyssey CLx imaging system and analyzed in Image Studio (LI-COR). 
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Fewer people are dying today from lung cancer than ever before, a fact to 
be celebrated, but one that is due largely to a decreased incidence of lung cancer 
due to fewer smokers, rather than better treatment and early detection strategies. 
The dismal five-year survival rate for lung cancer remains below 20% and over one 
million people will still die worldwide from lung cancer every year. While the number 
of lung cancers due to tobacco use is declining, smoking rates remain over 30% 
for most countries worldwide, and the use of e-cigs is increasing each year at an 
alarming pace. While the vast majority of lung cancers occur in those who have 
histories of, or who currently are, smoking, only 20% of smokers will acquire lung 
cancer. There are also a large number of individuals who develop lung cancer who 
have never smoked a day in their lives. These data suggest that other factors are 
also important in predisposing individuals to the development of lung cancer. This 
observation formed the basis for this work. The data presented in this dissertation 
can be summarized by the following: age-dependent host factors, including 
immunity and fibroblast-derived factors, influence lung cancer progression. 
Importantly, lung inflammation/tissue remodeling augments pulmonary metastasis 
in the aging lung, but not in young lungs, through mechanisms involving fibronectin 
EDA, which perhaps provides a scaffold for tumor cell proliferation, organization, 
and migration. These events seem to be amplified in females, suggesting a role 
for sex. We could find no role for redox oxidation in lung cancer progression. These 
data point to an interplay between lung aging and inflammation/remodeling in lung 
tumor progression. This dissertation underscores the need for further studies in 
the role of the host to unveil new anti-lung cancer therapies. 
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5.3 Strengths and Weaknesses 
Strengths 
 The work presented here has several strengths that have helped shed light 
on how age-dependent host factors influence lung cancer progression. First, this 
works unveils a previously unknown role for fibronectin EDA in lung cancer 
progression. Of particular interest is that EDA only plays a role in the aged lung, in 
the setting of lung injury. In our model, it did not play a role in uninjured lungs in 
young or old animals.  
Second, the use of multiple assays, several lung cancer and lung fibroblast 
cell lines as well as primary fibroblasts, and the complementary use of in vitro and 
in vivo models, allowed us to address an area for which there is no perfect model. 
All models, by nature, simplify the complexity human diseases. Of particular 
importance is our use of both immunocompetent and immunocompromised 
animals. While xenografts in immunocompromised animals are important in being 
able to study human cell lines by avoiding host rejection, they rarely metastasize 
and they do not allow one to dissect the role of host immunity in tumor growth and 
metastasis. This is a major drawback, as metastasis is what often kills patients. 
Studies often focus on the primary tumor, which is usually resected in the clinic. 
Our use of NSG mice was not to study human cell lines, but to determine what 
role, if any, immunity had in observations in immunocompetent animals.  
Lastly, the work presented here allowed for the careful characterization of 
the murine model of lung cancer by addressing a diverse range of host factors 
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ranging from age to redox to sex to tissue remodeling, many of which are observed 
in humans.  
 
Weaknesses 
 The work described here is by no means perfect. Science is based on 
experiments and observations, both of which can be flawed, which can then lead 
to flawed conclusions. Thus, it is imperative that the work be replicated and 
expanded to test mechanisms of action and potential interventions.  
 One weakness of this work is the use of the Lewis Lung Carcinoma model 
of lung cancer. While this model has been used extensively over the years, and 
much is known about it, it does not completely represent lung cancer development 
in the human. This is the case for all syngeneic and xenograft models.  For this 
reason, studies in are lab our ongoing using the KRAS model of spontaneous lung 
cancer development (see future directions).  
 Another weakness is that, other than the studies utilizing isolated primary 
lung fibroblasts, fibronectin EDA KO mice, and cMET inhibitors, there are limited   
mechanistic data. This is understandable as studies characterizing the model had 
to be completed first. Studies evaluating receptor function and intracellular 
signaling pathways will need to be performed in the future.  
 Fibronectin EDA was shown to be necessary for the increased susceptibility 
of the injured, aged lung to lung cancer metastasis. Admittedly, strategies for 
targeting fibronectin would be limited due to the high concentration of fibronectin 
in the plasma and other organs, but much work is being done in this area. Perhaps 
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a better approach would be to target fibronectin recognition by blocking its 
association with its various integrins [193].  
 
5.4 Future Directions 
Good science always raises more questions than it answers, and the work 
presented here is no different. There are several observations that remain 
unexplained in three keys areas presented in this dissertation: 
 
5.4.1 How does aging impact cancer progression? 
While we were able to show, in studies utilizing NSG mice, that immunity 
played a role in the increased susceptibility to lung cancer progression in the aged 
mice, there were still differences observed with aging (larger tumors in the lung), 
suggesting that other factors besides immunity play a role.  In addition to the role 
of fibronectin EDA, it would be interesting to test which integrins mediate this effect 
and what other ECMs, the various collagens, for example, influence cancer 
progression.  
We also plan to perform additional studies as outlined here, but with the B16 
melanoma cell line. These studies will be important to determine if the effect of 
aging that we observed is truly due to intrinsic factors in the host, or to intrinsic 
properties specific to LLC cells.  
 As mentioned previously, there are limitations to using syngeneic and 
xenograft models, as they do not fully recapitulate the human condition (e.g. 
angiogenesis and tissue microenvironment). For this reason, we plan to perform 
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additional studies using the KRAS model of spontaneous lung cancer 
development. KRAS is a potent oncogene that is mutated in 30% of human NSCLC 
cases [194]. This leads to a constitutively active pathway and the spontaneous 
development of lung carcinomas, which more closely resembles the human 
condition. By breeding fibronectin EDA mice with KRAS mice, we have developed 
animals that are lacking fibronectin EDA and that also spontaneously develop 
tumors. This will allow to evaluate the role of fibronectin EDA in lung cancer 
development. Studies are ongoing in our lab in this area. 
 Lastly, one must consider the role that epigenetics plays, not only in the 
aging process itself, but also in age-related disease susceptibility. Epigenetics 
refers to the study of inheritable changes in gene function without alterations to the 
underlying DNA sequence. This is important as it provides a target for intervention. 
At present, changes to the DNA sequence in humans are irreversible. The 
deterioration of cellular functions that occur with aging are characterized by 
epigenetic changes, which may be due to both internal and/or external stimuli 
[195]. Several epigenetic changes occur in aging including chromatin remodeling  
[196,197], but one of the best characterized modifications involve alterations in 
DNA methylation patterns at CpG sites in gene promoter regions, which typically 
become hypomethylated (hypermethylation has been observed in certain regions  
[198]) with age, and ultimately affect gene expression by preventing access of RNA 
polymerase II  [199]. This age-associated CpG hypomethylation is similar to global 
hypomethylation observed in most cancers and may provide a potential link 
between epigenetics and age-related cancer susceptibility in the elderly population 
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[200]. Indeed, it was recently shown that standardized measures of intrinsic 
epigenetic age acceleration (IEAA) were significantly associated with lung cancer 
incidence in aged females, suggesting that IEAA might serve as a useful biomarker 
for determining lung cancer susceptibility [201].  
   
5.4.2 What is the identity of soluble factor(s) in FCM that promote lung 
cancer? 
 We were able to identify and determine that HGF was responsible for 
several, but importantly not all, of the effects of FCM we observed in vitro. We were 
also able to rule out several components. Of interest were our data showing that 
charcoal-stripping of the FCM was able to prevent the protection from cisplatin in 
several NSCLC lines tested in vitro, although it was unable to block the mitogenic 
effect of FCM. This indicates that a non-polar, possibly lipid-based molecule is 
responsible for these effects. Additional work will need to be performed to discover 
the identity of this molecule(s).  
 
5.4.3 What is the role of sex in lung cancer progression? 
 In these studies, female mice were found to be more oxidized in their Eh 
Cys/CySS and were more susceptible to lung cancer progression in the LLC 
model. Our studies with the SAA diets suggested that these two were not related. 
This could however be due to limitations inherent in the SAA diets or the timing of 
the experiments. To investigate this further, we plan to treat female mice with 
sulforaphane, an isothiocyanate compound obtained from cruciferous vegetables 
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that has been shown to reduce the Eh Cys/CySS by increasing the levels of 
Slc7a11, a cystine-glutamate transporter. We also plan to repeat studies with the 
SAA diets in males, as we only performed studies using females.  
 One observation that remains unexplained is the increased oxidation of the 
Eh Cys/CySS in female mice. It is unknown if this also occurs in humans, or if this 
is simply a murine phenomenon. There is at least one report in the literature 
detailing increased oxidative stress in female C57BL/6 mice compared to males, 
as determined by electron para-magnetic resonance spectrometry and 
dihydroethidium oxidation in the brain [202]. Nevertheless, the factors responsible 
for this observation could explains other differences in female humans, such as an 
increased incidence of COPD in never-smokers.  
 Lastly, we observed that aged female mice had more fibronectin EDA 
protein levels in whole lung homogenates when compared to males. Whether this 
plays a role in their increased susceptibility to lung cancer progression in the LLC 
model remains to be seen.  
 Whenever the topic of sex is being investigated as a biological variable, one 
must take into account the obvious: the role of sex hormones. For this, we plan to 
repeat many of the studies described here, but in ovariectomized females, or 
castrated males. If differences are observed, then studies will again be repeated 
with hormone replacement using estradiol in females and testosterone in males. 
These studies will shed light on the role that sex hormones play in lung cancer 
progression and oxidative stress in males and females.  
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5.4.4 Could SAA diets play a role in prevention? 
 While our studies using SAA diets suggested that neither oxidation of the 
Eh Cys/CySS or the Eh GSH/GSSG played no role in lung cancer progression, 
this could be due to limitations of the LLC model. For this reason, we plan to repeat 
experiments with the SAA diets in KRAS mice, which spontaneously develop lung 
tumors, to determine what role, if any, thiol/disulfide couples play in lung cancer 
development.  Exposure of animals to the diets for prolonged periods of time would 
also help further define this observation.  
 
5.4.5 What is the role of the lung microbiome? 
 An emerging and exciting area of research pertains to the role of the 
microbiome (used synonymously with microbiota) in both normal and diseased 
states. The microbiome refers to the abundant and diverse bacterial, fungal, viral, 
and archaea populations that exist on and within the human body. In 2008, the NIH 
launched the Human Microbiome Project (HMP), which was tasked with studying 
how changes in the human microbiome associated with health and disease. The 
microbiome indeed has been shown to play crucial roles in maintaining normal 
homeostasis in the body, but has also been found to be altered in several disease 
states [203]. The most extensively studied microbiome is in the gut, which has the 
highest density of microorganisms in the body, with approximately 1014 bacteria 
[204]. Astonishingly, it has been reported that every human is host to trillions of 
bacterial cells, whose genome, in the gut, for example, contains at least 100 times 
as many genes as our own genome [205]. Alterations in the microbiome of the gut 
	 116	
(referred to as gut dysbiosis) are thought to be responsible for gastrointestinal 
diseases such as irritable bowel syndrome (IBS), peptic ulcers, and many gastric 
malignancies [206]. Of interest to this dissertation are studies indicating an effect 
of gut dysbiosis on the lung, a relationship referred to as the “gut-lung axis.” For 
example, individuals suffering from IBS often have impaired lung function [207]. A 
strong correlation between decreased microbial diversity in infancy and the 
development of asthma later in life has also been noted [208]. A variety of other 
lung disorders, such as COPD and cystic fibrosis, have also been linked to 
microbial dysbiosis [209–211]. In terms of cancer, a Danish population-based 
cohort study found that individuals with Crohn’s disease, but not ulcerative colitis, 
had an increased risk of lung cancer that was associated with female gender and 
smoking [212]. While research in this area is still in its infancy, there have been 
several promising studies detailing how we might take advantage of the 
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LIST OF ABBREVIATIONS 
 
aSMA  Alpha Smooth-Muscle Actin 
BAL   Bronchoalveolar Lavage  
BLEO  Bleomycin 
CCLE  Cancer Cell Line Encyclopedia 
cFN  Cellular Fibronectin 
cMET  Hepatocyte Growth Factor Receptor 
CAFs  Cancer-Associated Fibroblasts 
CO2  Carbon Dioxide 
COPD  Chronic Obstructive Pulmonary Disease 
Cys  Cysteine 
CySS  Cystine 
DAPI  4',6-diamidino-2-phenylindole 
DMEM  Dulbecco’s Modified Eagle Medium 	
E1  Estrone 
E2  17b-Estradiol 
ECAD  E-Cadherin 
E-cig  Electronic Cigarette 
ECM  Extracellular Matrix 
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EDA  Extra Domain A 
EDB  Extra Domain B 
Eh  Redox Potential 
EMT  Epithelial Mesenchymal Transition 
ERK  Extracellular Signal–Regulated Kinase 
FCM  Fibroblast Conditioned Media 
FBS   Fetal Bovine Serum 	
FGF  Fibroblast Growth Factor 
FN  Fibronectin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GSH  Glutathione 
GSSG  Glutathione Disulfide 
HE  Hematoxylin and Eosin 
HGF  Hepatocyte Growth Factor 
HIF  Hypoxia-Inducible Factor 
HMP  Human Microbiome Project 
HPLC  High-Performance Liquid Chromatography 
IACUC Institutional Animal Care and Use Committee 
IBS  Irritable Bowel Syndrome 
IEAA  Intrinsic Epigenetic Age Acceleration 
IPF  Idiopathic Pulmonary Fibrosis 
IV   Intravenous Injection  
KO  Knockout 
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LLC  Lewis Lung Carcinoma 
mTOR Mammalian Target of Rapamycin 
mV  Millivolts 
NAC  N-Acetyl Cysteine 
NCDs  Noncommunicable diseases 
NIH  National Institutes of Health 
NNK  4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone 
NNN  N'-nitrosonornicotine 
NSCLC Non-Small Cell Lung Cancer 
NSG  NOD scid gamma 
PAHs  Polycyclic Aromatic Hydrocarbons  
PBS   Phosphate Buffered Saline  
PBST  Phosphate Buffered Saline with Tween 
pFN  Plasma Fibronectin 
PI3K  Phosphatidylinositol-3-Kinases 
PLF   Primary Lung Fibroblasts 
RPM  Revolutions Per Minute  
RNS  Reactive Nitrogen Species 
ROS  Reactive Oxygen Species 
SAA  Sulfur Amino Acid 
SCLC  Small Cell Lung Cancer 
SDS   Sodium Dodecyl Sulfate  
TGFb  Transforming Growth Factor b  
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TSNAs Tobacco Specific Nitrosamines 
US  United States 
VIM  Vimentin 
WT  Wildtype 
x g  Relative Centrifugal Force
